e roche finance report f hoffmannla roche ltd finance report basel switzerland trademarks legally protected wwwrochecom finance brief key results sales core operating profit margin cer growth sales pharmaceuticals diagnostics group change sales mchf mchf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change mchf mchf chf cer net debt capitalisation debt equity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant currencies average rates year ended december core results core eps earnings per share exclude noncore items global restructuring charges amortisation impairment goodwill intangible assets allows transparent assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given therefinance brief roche roche group reported strong overall results core operating profit grew ahead sales core earnings per share increased constant exchange rates cer swiss franc stronger average rates major currencies notably japanese yen us dollar negative overall impact income statement cash flows expressed swiss francs sales group sales increased cer billion swiss francs growth swiss franc terms pharmaceuticals sales growth cer strong growth established new oncology products actemraroactemra rheumatoid arthritis lucentis ophthalmology partially offset decreases sales pegasys bonvivaboniva well loss evista sales japan diagnostics sales grew cer ahead market professional diagnostics major contributor operating results core operating profit increased cer billion swiss francs growth swiss franc terms sales growth cost savings various global restructuring plans offset higher operating costs investments key markets well impacts price pressure increased competition core operating margin increased percentage points research development expenditure grew cer billion swiss francs core basis driven investments oncology neuroscience therapeutic areas rd costs group sales ifrs operating results include noncore items billion swiss francs includes billion swiss francs amortisation impairment goodwill intangible assets billion swiss francs income reversal previous property plant equipment impairment nonoperating results net financial expenses decreased billion swiss francs billion swiss francs driven lower interest expenses partially offset higher net foreign exchange losses net income ifrs net income increased cer billion swiss francs swiss franc terms due strong core operating results lower financing costs lower global restructuring charges core earnings per share increased constant currencies swiss francs cash flows operating free cash flow billion swiss francs cer due higher operating profit free cash flow billion swiss francs cer due higher operating free cash flow lower interest paid repayment debt ahead schedule notes bonds issued finance genentech transaction repaid end financial position net working capital increased cer higher levels inventories due launches growth key products higher safety stock levels increased demand key markets mostly offset increased payables accrued liabilities net debt position improved billion swiss francs billion swiss francs credit ratings strong moodys standard poors aa shareholder return dividends proposal made increase dividends swiss francs per share represent th consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr representing combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles current liabilities operating segment information provisions contingent liabilities net financial expense debt income taxes equity attributable roche shareholders business combinations chugai global restructuring plans noncontrolling interests property plant equipment employee benefits goodwill pensions postemployment intangible assets benefits inventories equity compensation plans accounts receivable earnings per share nonvoting equity marketable securities security cash cash equivalents statement cash flows noncurrent assets risk management current assets related parties accounts payable subsidiaries associates noncurrent liabilities significant accounting policies report roche management internal control financial reporting report statutory auditor consolidated financial statements report independent auditor internal control financial reporting multiyear overview supplementary information roche securities roche hol ding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditor financial statements financial review roche group results sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf roche groups results showed growth core operating activities sales core operating profit constant exchange rates cer sales increasing regions investments continued develop product pipeline secure future sales growth notably research development increased core basis strong operating performance combined lower financing costs resulted increase core eps constant exchange rates strong operating results also evident operating free cash flow increased billion swiss francs sales sales pharmaceuticals division rose driven growth oncology portfolio significant growth recently launched medicines well established products key growth driver oncology franchise avastin mabtherarituxan zelboraf also making significant contributions sales actemraroactemra lucentis also increased key emerging markets showed growth led sales growth china diagnostics sales grew consolidating divisions leading market position major growth area professional diagnostics sales diabetes care declined core operating profit increased pharmaceuticals division growing diagnostics pharmaceuticals division cost sales grew due higher sales volumes initial costs implementing supply chain strategies future growth compliance costs negative exchange rate impacts increase marketing distribution costs driven investments expand business emerging markets increase patient access medicines research development increase arose mainly oncology neuroscience franchises focus new indications recently launched products developments pdl targeted therapy advancement programmes alzheimers disease diagnostics division profitability remained stable increased sales offset higher operating costs driven pricing impacts growth instrument placements especially us higher research development costs new medical device tax us roche group financial review roche finance report two major oneoff impacts core results release previously accrued reserves b drug discount program positive impact million swiss francs us pharmaceuticals sales million swiss francs core operating profit also million swiss francs income changes groups pension plans core operating profit group continued implementation number major restructuring initiatives position business future operational closure nutley site us announced completed schedule end october pharmaceuticals division published details investments increase global biologic medicine manufacturing network capacity part bulk drug production unit vacaville site california discontinued fully written brought back service resulting reversal previously incurred impairment charges million swiss francs diagnostics division continued implementation various global programmes diabetes care applied science businesses address long term profitability april group announced applied science business areas portfolio products integrated within business areas diagnostics division overall costs groups restructuring activities billion swiss francs lower compared impairment charges billion swiss francs recorded goodwill intangible assets notably product intangibles pharmaceuticals divisions hepatitis c virus hcv franchise goodwill tissue diagnostics business taken together growth underlying business increase ifrs net income constant exchange rates operating free cash flow billion swiss francs increase constant exchange rates increase reflects cash generation divisions partly offset higher capital expenditure property plant equipment investments intangible assets free cash flow billion swiss francs higher primarily due higher operating free cash flow lower interest payments groups debt continues repaid partially offset higher annual dividend swiss franc appreciated currencies particular japanese yen us dollar weakened euro overall impact negative results expressed swiss francs compared constant exchange rates impacts percentage points sales core operating profit core eps exchange rates used currency sensitivities given roche finance report roche group financial reviewincome statement change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests eps basic chf eps diluted chf core results sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core eps basic chf core eps diluted chf disclosed note consolidated financial statements discussed income statement restated following accounting policy changes adopted restated results causes reduction net financial income million swiss francs see also investor update march reconciliation previously published income statement provided note consolidated financial statements roche group financial review roche finance report sales sales increased constant exchange rates swiss francs us dollars billion swiss francs sales pharmaceuticals division rose franchise avastin mabtherarituxan actemra roactemra lucentis growing strongly emerging market e sales pharmaceuticals grew led growth china represent divisions sales diagnostics division recorded sales billion swiss francs increase constant exchange rates consolidating leading market position major growth area professional diagnostics represents half divisions sales grew diabetes care sales decreased divisional operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operating free cash flow increase cer margin percentage point increase core operating results groups core operating profit increased constant exchange rates swiss francs groups core operating profit margin improved percentage points sales two major oneoff impacts core results release sales reserves previously accrued b drug discount program us positive impact million swiss francs sales million swiss francs core operating profit also income million swiss francs recorded changes groups pension plans constant exchange rates effects combined positive margin impact percentage points group percentage points pharmaceuticals division percentage points diagnostics division excluding two factors core operating profit grew group pharmaceuticals division diagnostics division currency translation negative impact percentage points operating results minor currency effect groups core operating margin positive effect percentage points pharmaceuticals division offset negative effect percentage points diagnostics division roche finance report roche group financial reviewpharmaceuticals division division increased core operating profit constant exchange rates driven growth underlying business increase sales cost sales increased due higher sales volumes initial costs implementing supply chain strategies future growth compliance costs negative exchange rate impacts research development costs increased mainly oncology neuroscience franchises increase general administration costs stable percentage sales diagnostics division core operating profit increased driven growth underlying business increase sales cost sales increased sales growth due pricing impacts also growth instrument placements especially us marketing distribution costs decreased result lower spending diabetes care former applied science businesses due lower bad debt expenses research development costs increased due continuing investments nextgeneration platforms general administration costs increased due costs new medical device tax us ongoing systems projects increases partly offset income recorded changes groups pension plans global restructuring plans group continued implementation several major global restructuring plans initiated prior years notably reorganisation research development pharmaceuticals division programmes address longterm profitability diabetes care former applied science businesses diagnostics additionally income million swiss francs reversal previously incurred impairment charges bulk drug production unit vacaville site california global restructuring plans costs incurred millions chf diagnostics pharma rd plans total global restructuring costs employeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs includes restructuring diabetes care former applied science business areas includes closure nutley site associated infrastructure environmental remediation costs includes operational excellence programme pharmaceuticals diagnostics diagnostics division diabetes care applied science restructuring april group announced applied science business areas portfolio products integrated within business areas diagnostics division streamline decisionmaking enhance technology flow research use clinical setting september roche diabetes care announced autonomy speed initiative enable business focus diabetes care specific requirements speed processes decisionmaking drive efficiencies total costs million swiss francs incurred mainly headcount reductions itrelated costs site closure costs addition goodwill impairment charges million swiss francs incurred writeoff goodwill innovatis life sciences acquisitions former applied science business area roche group financial review roche finance report pharmaceuticals division research development reorganisation june group announced streamlining research development activities within pharmaceuticals division planned operational closure us site nutley new jersey completed schedule end total costs million swiss francs incurred costs include additional provisions million swiss francs cover site running costs expected divestment impairment million swiss francs carrying value nutley site based recent external property market data costs employeerelated site closure reorganisational matters million swiss francs first results environmental investigations showed expected cost remediation may lower originally expected accordingly environmental provisions reduced million swiss francs global restructuring plans october pharmaceuticals division announced investments increase global biologic medicine manufacturing network capacity meet rising demand licensed biologics expected pipeline growth part bulk drug production unit vacaville site california discontinued fully written put back service resulted income million swiss francs reversal previously incurred impairment charges costs million swiss francs incurred previously announced operational excellence programme mainly employeerelated site closure costs pharmaceuticals division employeerelated site closure costs diagnostics division sites burgdorf switzerland graz austria plans totalled million swiss francs merger acquisitions july group acquired controlling interest constitution medical investors inc cmi us private company based massachusetts cmi developer highly innovative hematology testing system designed provide faster accurate diagnosis bloodrelated diseases helping improve patient care cmi reported diagnostics operating segment part professional diagnostics business area purchase consideration million us dollars cash million us dollars contingent consideration arrangement impairment goodwill intangible assets impairment charges goodwill intangible assets million swiss francs million swiss francs incurred applied science restructuring initiative described based latest business plans prepared second half goodwill impairment million swiss francs recorded tissue diagnostics business area within diagnostics division main factor leading impairment reduced revenue expectations us follow recent changes college american pathologists guidelines use negative reagent controls immunohistochemistry testing reduced volumes changes reduced reimbursement amount laboratories addition unrelated global restructuring impairments totalling million swiss francs recorded pharmaceuticals division following portfolio reassessment within hepatitis c virus hcv franchise impairment charges million swiss francs recorded pharmaceuticals division various smaller projects details given notes consolidated financial statements pensions postemployment benefits operating income million swiss francs recorded past service costs changes groups pension plans switzerland united kingdom germany represents onetime impact adjustment pension liability plan changes amount million swiss francs recorded pharmaceuticals division million swiss francs diagnostics division remaining million swiss francs income allocated corporate mainly attributable previously divested businesses addition us pension plans made offer deferred vested members settle part defined benefit obligation lump sum payment resulted onetime settlement gain ifrs results million swiss francs details given note consolidated financial statements roche finance report roche group financial reviewlegal environmental settlements addition reversal environmental remediation costs million swiss francs nutley site mentioned million swiss francs legal environmental costs recorded unrelated global restructuring plans include increase million swiss francs estimated remediation costs landfill site near grenzach germany previously used manufacturing operations closed years ago treasury taxation financing costs billion swiss francs decrease interest expenses lower constant exchange rates debt repaid financial income expense net expense million swiss francs mainly due losses following devaluation venezuelan bolivar foreign exchange hedge costs core tax expenses increased billion swiss francs groups effective core tax rate stable main factors higher percentage core profit contribution coming tax jurisdictions relatively higher local tax rates average group rate notably us mostly offset retrospective reenactment us research development tax credit rules january net income earnings per share ifrs net income diluted eps increased constant exchange rates driven strong operating performance significantly lower global restructuring expenses lower financing costs core basis excludes noncore items global restructuring costs amortisation impairment goodwill intangible assets net income core eps increased driven strong operating performance lower financing costs core eps grew excluding positive impacts b drug discount program us changes groups pension plans supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results financial position change change mchf mchf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt pensions income taxes nonoperating assets net total net assets compared start year swiss franc appreciated significantly japanese yen also slight appreciation us dollar brazilian real slight weakening euro effects resulted negative translation impact balance sheet positions december exchange rates used given roche group financial review roche finance report pharmaceuticals division net working capital increased constant exchange rates mainly driven increase inventories due recent upcoming product launches expected higher sales demand also higher levels safety stock selected products temporary bridging stocks result changes supply chain strategy trade receivables decreased mainly result continuing strong collections offset effects underlying business growth trade payables increased following initiatives improve cash management including extension payment terms longterm net operating assets grew mainly due increases property plant equipment main factor biologic medicine manufacturing network investments resulted impairment reversal bulk drug production unit vacaville site us previously impaired partially offset impairment intangible assets hepatitis c virus hcv franchise diagnostics decrease net working capital driven increase trade payables driven extended payment terms well increased accruals including employee benefits lower levels inventories trade receivables stable decreases european markets offset increases emerging markets notably china long term net operating assets stable increases property plant equipment facilities germany instrument placements offset impairments goodwill intangible assets decrease net debt position mainly driven free cash flow billion swiss francs transactions equity hedge groups employee stock option programmes increased net debt billion swiss francs net pension liabilities decreased billion swiss francs due changes discount rates pension plan changes referred net tax assets increased mainly due deferred tax effect equity compensation plans increased due increase price underlying equity free cash flow change change mchf mchf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid dividends paid free cash flow groups operating free cash flow billion swiss francs increase constant exchange rates increase core operating profit partly offset higher capital expenditure property plant equipment investments intangible assets increases net working capital noted comments financial position higher cash utilisation restructuring legal provisions also several noncash items core net income including income changes groups pension plans free cash flow billion swiss francs increase constant exchange rates higher operating free cash flow lower interest payments partly offset higher annual dividend payments group refined calculation free cash flow exclude impact employee stock options line peer group see details comparative free cash flow information restated accordingly roche finance report roche group financial reviewpharmaceuticals division operating results pharmaceuticals division operating results change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps roche group financial review roche finance report sales overview pharmaceuticals division sales therapeutic area change sales sales therapeutic area mchf mchf cer oncology immunology infectious diseases ophthalmology neuroscience therapeutic areas total sales pharmaceuticals division sales increased constant exchange rates growth driven oncology portfolio well actemraroactemra lucentis increases offset lower sales pegasys loss chugais evista sales following termination comarketing agreement japan expected decline bonviva boniva sales growth primarily driven franchise avastin mabtherarituxan actemraroactemra lucentis main growth drivers represent portfolio together generated billion swiss francs additional sales sales us benefited release previously accrued reserves b drug discount program million swiss francs half mabtherarituxan oncology demand established products grew due expanded use existing indications furthermore growth driven franchise following additional approvals perjeta launch kadcyla us europe zelboraf also continued significant growth contributor sales immunology increased due strong growth actemraroactemra regions reflecting strong uptake actemra monotherapy treatment also due growth mabtherarituxan rheumatoid arthritis continued growth ophthalmology lucentis sales benefited approval less frequent dosing regimen wet agerelated macular degeneration wamd well increased sales retinal vein occlusion rvo diabetic macular edema dme geographic data following sales tables presented using new organisational structure pharmaceuticals division see investor update march roche finance report roche group financial reviewproduct sales pharmaceuticals division sales change sales sales mchf mchf cer oncology avastin herceptin mabtherarituxan xeloda tarceva zelboraf perjeta kadcyla neutrogin others total oncology immunology mabtherarituxan actemraroactemra cellcept xolair pulmozyme others total immunology infectious diseases pegasys valcytecymevene tamiflu rocephin others total infectious diseases ophthalmology lucentis total ophthalmology neuroscience madopar others total neuroscience therapeutic areas activasetnkase neorecormonepogin mircera nutropin bonvivaboniva others total therapeutic areas total sales total mabtherarituxan sales million swiss francs million swiss francs split oncology immunology franchises previous reports total neorecormonepogin sales split renal anemia oncology franchises roche group financial review roche finance report mabtherarituxan change sales sales mchf mchf cer united states europe japan international total sales mabtherarituxan nonhodgkins lymphoma nhl chronic lymphocytic leukemia cll rheumatoid arthritis ra well granulomatosis polyangiitis gpa microscopic polyangiitis mpa global sales growth driven increased use across oncology rheumatoid arthritis indications sales growth oncology franchise ra franchise sales grew us sales billion swiss francs increase benefiting release sales reserves b program excluding impact million swiss francs us sales rose sales rose international region growth china increased demand treatment diffuse large bcell lymphoma type nhl herceptin change sales sales mchf mchf cer united states europe japan international total sales perjeta change sales sales mchf mchf cer united states europe japan international total sales kadcyla change sales sales mchf mchf cer united states europe japan international total sales roche finance report roche group financial reviewher franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin sales grew us international region excluding release sales reserves million swiss francs b program us sales rose us growth resulted increased usage breast gastric cancer international region grew subregions asia grew result breast cancer patient access programme testing initiatives sales latin america increased private public sectors european sales stable sales japan grew recently launched perjeta kadcyla continued growth drivers strong uptake recognised benefits compared treatment regimens total franchise grew avastin change sales sales mchf mchf cer united states europe japan international total sales avastin advanced colorectal breast lung kidney ovarian cancer relapsed glioblastoma type brain tumour global sales grew mainly due increased use established indications colorectal lung breast cancer well newer indication ovarian cancer ovarian colorectal cancer indications main drivers behind sales increase europe avastin sales us grew result expanded use colorectal cancer also benefited release b program sales reserves excluding impact million swiss francs us sales rose growth international region higher sales latin america driven increased use colorectal ovarian cancer indications brazil also higher sales asia subregion china growing driven colorectal cancer indication growth japan primarily due use colorectal breast lung cancer lucentis change sales sales mchf mchf cer united states total sales lucentis wet agerelated macular degeneration wamd macular edema following retinal vein occlusion rvo diabetic macular edema dme us sales grew driven growth rvo dme indications stable market share wamd following approval given earlier year less frequent dosing regimen xeloda change sales sales mchf mchf cer united states europe japan international total sales roche group financial review roche finance report xeloda colorectal stomach breast cancer sales increased growth driven primarily china also japan increased penetration adjuvant colon cancer acc metastatic colorectal cancer mcrc sales europe impacted price pressure loss exclusivity december tarceva change sales sales mchf mchf cer united states europe japan international total sales tarceva advanced nonsmall cell lung nsclc pancreatic cancer sales rose growth us china japan growth resulted approval penetration firstline epidermal growth factor receptor egfr mutationpositive nsclc indication europe partially compensated decrease patient share secondline nsclc international region growth asia supported additional reimbursement approvals pegasys change sales sales mchf mchf cer united states europe japan international total sales pegasys hepatitis b c sales decreased mainly us europe due treatment deferrals anticipation expected launch interferonfree combination therapies international region growth asia due expanding access patients markets firstgeneration triple therapies recently launched actemraroactemra change sales sales mchf mchf cer united states europe japan international total sales actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis sales continued grow approved indications regions result continued strong uptake monotherapy rheumatoid arthritis sales billion swiss francs increases particularly us europe actemraroactemra continues gain market share marketing reimbursement approvals additional countries continue expand patient access actemraroactemra actemra subcutaneous formulation approved japan march us october adults living moderately severely active rheumatoid arthritis roche finance report roche group financial reviewneorecormonepogin change sales sales mchf mchf cer united states europe japan international total sales mircera change sales sales mchf mchf cer united states europe japan international total sales anemia franchise neorecormonepogin mircera anemiarenal anemia declining highly competitive market combined sales roches neorecormon chugais epogin epoetin beta declined sustained decline sales neorecormon epogin partly offset growth sales longeracting erythropoiesisstimulating agent mircera rose million swiss francs much growth due increasing number patients switching starting treatment mircera place neorecormonepogin strongest contributions higher mircera sales came japan cellcept change sales sales mchf mchf cer united states europe japan international total sales cellcept prevention solid organ transplant rejection sales stabilised return growth us due delay generic competition entering market growth japan offsetting continued decline europe following patent expiry continued growth japan reflects position cellcept standard care ahead launch generics became available end roche group financial review roche finance report tamiflu change sales sales mchf mchf cer united states europe japan international total sales tamiflu influenza b sales increases us offset lower sales seasonal pandemic use japan zelboraf change sales sales mchf mchf cer united states europe japan international total sales zelboraf braf mutationpositive metastatic melanoma sales grew regions zelboraf approved countries receiving increasing reimbursement coverage zelboraf established standard care braf mutationpositive metastatic melanoma key markets us france germany uk pharmaceuticals division sales region change sales sales region mchf mchf cer united states europe japan international eemea latin america asiapacific regions total sales table geographic sales data shown pharmaceuticals division presented using new organisational structure pharmaceuticals division see investor update march eastern europe middle east africa roche finance report roche group financial reviewunited states sales grew us dollar terms excluding impact reserves release b drug discount program leading products oncology medicines mabtherarituxan avastin franchise sales billion swiss francs billion swiss francs billion swiss francs respectively products main growth drivers lucentis activasetnkase xolair tamiflu actemraroactemra gazyva received approval november previously untreated chronic lymphocytic leukemia sales remainder million swiss francs europe sales increased constant exchange rates despite impacted pricing pressures growth mainly driven oncology products avastin zelboraf perjeta mabtherarituxan addition continued sales growth actemraroactemra partially offset lower neorecormon bonvivaboniva sales japan sales grew japanese yen terms results japan impacted loss evista sales following termination comarketing agreement negative impact percentage points sales growth major growth drivers avastin sales million swiss francs edirol million swiss francs also growth actemraroactemra herceptin mabtherarituxan recently launched perjeta bonvivaboniva international sales increased constant exchange rates driven asiapacific latin america subregions growth asiapacific mainly due oncology products especially herceptin avastin mabthera rituxan xeloda china main driver region overall sales growth latin america sales growth driven avastin herceptin actemra despite pricing pressure political uncertainties subregion eemea sales grew underlying growth offset timing delays tender sales sales region also negatively impacted political instability several markets pharmaceuticals division sales e leading emerging markets change sales sales country mchf mchf cer total brazil china india mexico russia south korea turkey total sales total sales e key emerging markets grew sales growth led china substantial contribution brazil growth china reflects efforts made expand patient access medicines investment strategy expand geographical coverage medical care growth brazil resulted inclusion several key products reimbursement scope public healthcare provision sales declined mexico due delays market approvals public sector purchases growth turkey result strong sales key oncology products roche group financial review roche finance report operating results pharmaceuticals division royalties operating income change mchf mchf cer royalty income income outlicensing agreements income disposal products total ifrs core basis royalties operating income decrease constant exchange rates due lower income disposal products lower due four large transactions year increase royalty income japan increased royalties elsewhere higher sales outlicensed products humira enbrel partly offset milestone income eylea base effect back royalty income million swiss francs received increase outlicensing income mainly due outlicensing agreements japan pharmaceuticals division cost sales change mchf mchf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis cost sales core costs increased constant exchange rates mainly due higher sales volumes initial costs implementing supply chain strategies future growth compliance costs negative exchange rate impacts percentage sales cost sales increased slightly royalty expenses higher driven newly launched oncology products increased sales avastin tamiflu addition back royalty expenses million swiss francs due latest developments sanofi arbitration see also note consolidated financial statements expenses collaboration profitsharing agreements increased mainly driven higher copromotion expenses result higher sales mabtherarituxan including related release b program sales reserves increased sales xolair tarceva net income global restructuring plans due million swiss francs reversal previously incurred impairment charges bulk drug production unit vacaville site california see note consolidated financial statements pharmaceuticals division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plans total ifrs basis roche finance report roche group financial reviewmarketing distribution core costs increased constant exchange rates percentage sales ratio improving sales marketing efforts focussed continued business expansion increasing patient access medicines particular emerging markets asia significant investments also made support existing oncology portfolio newly launched products perjeta kadcyla gazyva pharmaceuticals division research development change mchf mchf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis research development core costs increased constant exchange rates percentage sales decreased increased investments oncology neuroscience therapeutic areas oncology additional activities focussed new indications recently launched products developments pdl targeted therapy progression programmes alzheimers disease main area increased activity neuroscience area partially offset lower spending therapeutic areas cardiovascular inflammation discontinuation inflammation research nutley addition pharmaceuticals division capitalised million swiss francs million swiss francs intangible assets inlicensing pipeline compounds technologies impairments intangible assets include million swiss francs following portfolio reassessment within hepatitis c virus hcv franchise million swiss francs respect projects amortisation intangible assets increased due recent investments global restructuring costs million swiss francs recorded consisting mainly employeerelated costs outside services closure nutley site pharmaceuticals division general administration change mchf mchf cer administration pensions past service costs gains losses disposal property plant equipment gains losses divestment subsidiaries business taxes capital taxes general items general administration core basis global restructuring plans alliances business combinations legal environmental settlements pensions settlement gains losses total ifrs basis roche group financial review roche finance report general administration core costs increased constant exchange rates largely stable percentage sales includes beneficial impact million swiss francs income changes groups pension plans increase administration costs mainly result shift finance headcount corporate also increase business taxes including costs us branded pharmaceutical product fee million swiss francs million swiss francs global restructuring costs mainly include site closure costs nutley consisting employeerelated costs property taxes outside services provisions million swiss francs cover site running costs expected divestment legal environmental settlement costs mainly relate legal matters described note consolidated financial statements roche pharmaceuticals chugai subdivisional operating results pharmaceuticals subdivisional operating results millions chf roche pharmaceuticals pharmaceuticals chugai division sales external customers within division core operating profit margin sales external customers operating profit margin sales external customers operating free cash flow margin sales pharmaceuticals division total core operating profit operating profit include elimination million swiss francs million swiss francs unrealised intercompany profits roche pharmaceuticals chugai sales core operating profit roche pharmaceuticals increased significantly underproportional cost growth marketing distribution research development combined stable general administration costs fall exchange rate japanese yen negative impact approximately chugai results expressed swiss francs chugais core operating profit increased line increase sales third parties gross profit sales driven higher domestic sales despite loss evista sales income outlicensing agreements royalties increased significantly operating expenses grew mainly due increased rd activities higher md spend mainly driven product launches operating free cash flow chugai decreased mainly result net working capital movements significant increase inventories safety stocks decrease accounts payable driven timing material purchases roche pharmaceuticals roche finance report roche group financial reviewfinancial position pharmaceuticals division net operating assets movement movement change change transactions cta mchf mchf chf cer mchf mchf trade receivables inventories trade payables net trade working capital receivablespayables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given consolidated financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start year swiss franc appreciated significantly japanese yen also appreciation us dollar brazilian real effects resulted overall negative translation impact balance sheet positions million swiss francs december exchange rates used given net working capital increase net trade working capital constant exchange rates due increases inventories partly offset reductions trade receivables increase trade payables higher levels inventories recent upcoming product launches actemraroactemra herceptin subcutaneous sc formulations kadcyla perjeta also expected higher sales demand established products also increases safety stocks selected existing products temporary bridging stocks result changes supply chain strategy trade receivables decreased despite sales increase result continuing strong collections notably europe eemea regions trade payables increased following initiatives improve cash management including extension payment terms decrease net liability receivables payables due mainly increase prepaid expenses royalty receivables longterm net operating assets increased increase property plant equipment lower provisions partially offset decrease intangible assets movement property plant equipment mainly attributable capital expenditure projects described free cash flow section impairment reversal bulk drug production unit vacaville site us intangible assets decreased due impairments following portfolio reassessment within hepatitis c virus hcv franchise impairments provisions decreased due utilisation restructuring legal provisions addition nutley environmental provision transferred pharmaceuticals division corporate managed centrally planned site divestment roche group financial review roche finance report free cash flow pharmaceuticals division operating free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales detailed breakdown provided pharmaceuticals divisions operating free cash flow increased constant exchange rates billion swiss francs increased cash generation underlying business represented growth core operating profit partly used increases net working capital noted comments financial position operating profit net cash adjustments also increased adjustment various noncash items core results largely offset capital expenditure property plant equipment relates investments efficiency improvements manufacturing facilities increased production capacity particular us also transfer functions nutley site locations infrastructure expansion resulting business growth asia increased expenditure site developments basel roche finance report roche group financial reviewdiagnostics division operating results diagnostics division operating results change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps sales diagnostics division sales grew ahead global vitro diagnostics market regions contributing sales growth constant exchange rates billion swiss francs growth predominantly driven continued strong demand immunoassays platforms used clinical laboratories roches professional diagnostics business area regionally emerging markets diabetes care sales decreased due continued market challenges reimbursement changes blood glucose monitoring key markets notably us molecular diagnostics grew continued strong uptake hpv test us main growth drivers blood screening products returning growth well worldwide growth oncology tests nucleic acid purification nap products life sciences tissue diagnostics sales increased market growth regions except us grew lower rate due reimbursement guidelines changes roche group financial review roche finance report april group announced applied science business areas portfolio products would integrated within groups diagnostics business areas polymerase chain reaction technology pcr nucleic acid purification nap biochemical reagents lines managed molecular diagnostics custom biotech portfolio moved professional diagnostics dedicated unit established focus solely sequencing sales information reclassified retrospectively sales sequencing business reported part results molecular diagnostics total divisional sales unchanged diagnostics division sales business area change sales sales business area mchf mchf cer professional diagnostics diabetes care molecular diagnostics tissue diagnostics total sales professional diagnostics change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales professional diagnostics sales grew respective market extended roches position market leader strong growth driven immunoassay clinical chemistry businesses coagulation patient selfmonitoring hematology also contributed good performance regions achieved sales growth asiapacific region main regional growth driver sales smaller latin america region also grew north america sales increased cobas cobas product lines automation solutions main contributors emea region sales grew mainly due immunoassay tests clinical chemistry products coagulation patient selfmonitoring business strong growth north america japan sales grew immunoassay business continued growth contributed quarter divisions total sales tests markers oncology thyroid disorders cardiac diseases womens health including vitamin infectious diseases make majority immunoassay sales hematology business showed strong growth momentum russia latin america key milestone business area launch new cobas instrument fully automated workflow series managing numerous routine laboratory tasks simplifies operations customers reducing manual handling samples increases costefficiencies processing urgent samples twice speed earlier version system system available globally except us since launch achieved good market uptake due reorganisation former applied science business area custom biotech portfolio part professional diagnostics business area reflected comparative information roche finance report roche group financial reviewdiabetes care change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales diabetes care decrease sales reflects reimbursement cuts blood glucose monitoring supplies especially us ongoing price pressure key markets continued competition lowcost providers sales decreased north america due reimbursement cuts important segments us market business grew asiapacific latin america sales stable emea several countries affected lowcost providers sales japan lower sales accuchek mobile targeted frequent testers grew whereas sales oldgeneration accu chek compact advantage meters continued decline sales insulin delivery systems grew growth blood glucose monitoring bgm strip volumes meters placements offset continuing price pressures bgm sector total leading decline global sales diabetes care business business continued market launches nextgeneration versions existing brands accuchek active accuchek avivaperforma meters received fda clearance accuchek aviva expert system us accuchek active meter nextgeneration nocode accuchek avivaperforma meter launched third quarter globally except us nocode accuchek nano smartview meter test strips already available since roche diabetes care initiated restructuring notably research development activities also including marketing manufacturing activities sustain longterm profitability restructuring steps taken activities continue molecular diagnostics change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales molecular diagnostics underlying growth molecular diagnostics business excluding sequencing sales main contributors tests human papilloma virus hpv nucleic acid purification naprealtime pcr qpcr reagents systems life sciences market products blood screening sales growth reported regions north america main growth driver hpv test sales blood screening sales blood screening also grew asiapacific emea region sales growth napqpcr reagents led growth sales oncology companion tests japan sales grew sales blood screening represents significant proportion business areas total sales showed return growth second half impacts timing differences ordering patterns seen first half year normalised sales oncology companion diagnostic tests area high medical value also showed significant growth roche group financial review roche finance report following reorganisation former applied science business area realtime pcr technology nap nucleic acid purification portfolio biochemical reagents part molecular diagnostics business sales sequencing business reported part results molecular diagnostics changes reflected comparative information tissue diagnostics change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales tissue diagnostics sales growth mainly due advanced staining reagents business regions recording sales growth north america sales increased lower global growth due recent changes us guidelines reimbursements see sales growth outside us asiapacific reporting sales growth advanced staining notably china australia south korea emea sales increase due strong growth reagent sales new primary staining instrument sales sales primary staining strong contribution special stains business revenues external personalised healthcare partners sales companion tests continued grow cintec plus cytology test fully automated cellbased assay used cervical cancer screening obtained ce mark december based latest business plans prepared second half goodwill impairment million swiss francs recorded tissue diagnostics business within diagnostics division main factor leading impairment reduced revenue expectations us follow recent changes college american pathologists guidelines use negative reagent controls immunohistochemistry testing reduced volumes changes reduced reimbursement amount laboratories diagnostics division sales region change sales sales region mchf mchf cer europe middle east africa emea north america asiapacific latin america japan total sales divisional sales growth primarily driven asiapacific emea europe middle east africa latin america regions demand particularly high china sales rose immunodiagnostics clinical chemistry reagents key growth drivers asiapacific region sales growth emea region led professional diagnostics tissue diagnostics also contributing latin america professional diagnostics molecular diagnostics tissue diagnostics showed solid growth north america sales grew strong us sales growth immunoassays coagulation monitoring molecular diagnostics particular hpv blood screening businesses growth us offset sales decline diabetes care due significant cuts reimbursement immunoassay sales grew largest contributor growth japan roche finance report roche group financial reviewdiagnostics division sales e leading emerging markets change sales sales country mchf mchf cer brazil china india mexico russia south korea turkey total sales e markets contributed sales growth mainly professional tissue diagnostics business areas brazil division reinforced market leadership ivd market south korea growth driven commercial laboratory automation projects professional tissue diagnostics enhanced testing efficiency customer sites ongoing focus innovative safe blood testing patients across whole india division doubled sites nucleic acid tests nat resulting growth molecular diagnostics operating results diagnostics division royalties operating income change mchf mchf cer royalty income income outlicensing agreements income disposal products total ifrs core basis royalties operating income decrease constant exchange rates driven lower royalty income mainly result back royalty payments million swiss francs received reoccur diagnostics division cost sales change mchf mchf cer manufacturing cost goods sold period costs royalty expenses impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis roche group financial review roche finance report cost sales core costs increased constant exchange rates due increase manufacturing cost goods sold period costs overall growth core costs higher sales growth due pricing impacts also growth instrument placements especially us increased diabetes meter placements increase partially offset onetime vat refund million swiss francs related meter placements prior years resulted cost sales ratio compared global restructuring costs mainly due reorganisation former applied science business closure sites graz austria burgdorf switzerland amortisation product intangibles decreased intangible assets became fully amortised diagnostics division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis marketing distribution core costs decreased constant exchange rates due lower spending diabetes care former applied science business following restructuring initiatives bad debt expenses also lower decreases partially offset increased spending sales force distribution professional diagnostics molecular diagnostics asiapacific latin america regions marketing distribution costs increased due sales force expansion penetrate emerging markets offset lower spending emea region core basis marketing distribution costs percentage sales compared global restructuring costs mainly due reorganisations diabetes care former applied science businesses improve efficiency marketing distribution activities diagnostics division research development change mchf mchf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis research development core costs increased constant exchange rates driven increased spending instrument development costs major platforms professional molecular diagnostics furthermore research development costs increased due acquisition constitution medical investors inc boston us former applied science business expenses declined significantly result ongoing restructuring diabetes care costs remained stable result cost containment programmes initiated percentage sales research development core costs increased global restructuring costs mainly related reorganisation applied science business closure site graz austria intangible asset impairments million swiss francs incurred part reorganisation roche finance report roche group financial reviewdiagnostics division general administration change mchf mchf cer administration pensions past service costs gains losses disposal property plant equipment business taxes capital taxes general items general administration core basis global restructuring plans impairment intangible assets alliances business combinations legal environmental settlements pensions settlement gains losses total ifrs basis general administration core costs increased constant exchange rates increase administration costs due higher employee costs professional diagnostics staffing global projects ramping new developing affiliates well increases certain legal costs business taxes increased due new us medical device tax costs million swiss francs general items include several ongoing systems projects standardise automate centralise business processes increases offset income million swiss francs recorded changes groups pension plans percentage sales core costs increased global restructuring costs mainly due global projects employeerelated costs reorganisation former applied science business addition goodwill impairment charges million swiss francs recorded tissue diagnostics business million swiss francs incurred writeoff goodwill life sciences innovatis acquisitions former applied science business financial position diagnostics division net operating assets movement movement change change transactions cta mchf mchf chf cer mchf mchf trade receivables inventories trade payables net trade working capital receivablespayables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow include cash movements full consolidated balance sheet given consolidated financial statements reconciliation balance sheet information given roche group financial review roche finance report currency translation effects balance sheet amounts compared start year swiss franc appreciated us dollar slightly weakened euro effects resulted overall negative translation impact balance sheet positions million swiss francs december diagnostics division significant net asset position japanese yen appreciation swiss franc japanese yen minor impact exchange rates used given net working capital net trade working capital decreased driven increase trade payables decrease inventories trade payables increased due extended payment terms inventories decreased due increased inventory provisions trade receivables stable high collections partially offset increases following growth business emerging markets notably china increase net liability receivablespayables main factor behind increase receivablespayables higher accruals including employee benefits partially offset increase prepaid expenses longterm net operating assets remained stable constant exchange rates decrease intangible assets offset increases investments property plant equipment property plant equipment increased due higher instrument placements site expenditure germany goodwill intangible assets decreased due impairments tissue diagnostics former applied science business area partially offset acquisition constitution medical investors inc us provisions decreased due net utilisation restructuring provisions free cash flow diagnostics division operating free cash flow change mchf mchf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales detailed breakdown provided operating free cash flow diagnostics division increased billion swiss francs cash generation business supported decrease net working capital mainly due increases payables noted comments financial position operating profit net cash adjustments decreased core operating profit increased difference due several noncash items including income changes groups pension plans cash utilisation restructuring provisions lower bad debt expenses capital expenditure property plant equipment billion swiss francs results investment facilities germany instrument placements particularly china us germany roche finance report roche group financial reviewcorporate operating results corporate operating results summary change mchf mchf cer administration pensions past service costs business taxes capital taxes general items general administration costs core basis global restructuring plans alliances business combinations legal environmental settlements pensions settlement gains losses total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow see pages definition core results core eps general administration core costs decreased constant exchange rates due positive impact million swiss francs recorded changes groups pension plans mainly attributable previously divested businesses administration expenses decreased mainly due shift headcount pharmaceuticals division increase general items driven costs related ongoing systems projects total costs ifrs basis decreased environmental expenses included increase estimated costs remediation landfill site grenzach germany million swiss francs partly offset release million swiss francs environmental remediation provisions nutley site us corporate operating free cash flow showed higher outflow due reduction accounts payable notably accruals employee benefits major reason decrease core costs noncash income changes groups pension plans roche group financial review roche finance report foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer swiss francs change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit exchange rates swiss franc december average december average usd eur jpy compared swiss franc stronger many currencies particular japanese yen also us dollar weakened others notably euro overall impact negative income statement free cash flow results expressed swiss francs compared constant exchange rates sales developments resulted negative impact percentage points equivalent billion swiss francs translated swiss francs currency translation exposure operating profit mitigated group majority cost base located outside switzerland sensitivity group sales core operating profit absolute terms movement average foreign currency exchange rates swiss franc shown table currency sensitivities impact change average exchange rate sales core operating profit versus swiss franc mchf mchf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro costs sales marketing also administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs mainly concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany obviously large majority chugais costs denominated japanese yen roche finance report roche group financial reviewtreasury taxation results treasury taxation results change change mchf mchf chf cer ifrs results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests financial position treasury taxation net debt pensions income taxes financial noncurrent assets derivatives net collateral net interest payable nonoperating assets net total net assets liabilities free cash flow treasury taxation treasury activities taxes paid dividends paid total disclosed note consolidated financial statements discussed income statement restated following accounting policy changes adopted restated results causes reduction net financial income million swiss francs see also investor update march reconciliation previously published income statement provided note consolidated financial statements see pages definition core results core eps roche group financial review roche finance report financing costs financing costs million swiss francs decrease million swiss francs compared main driver decrease interest expense reflects continued repayment debt incurred finance genentech transaction loss early redemption debt million swiss francs compared million swiss francs net interest cost pension plans remained stable million swiss francs full analysis financing costs given note consolidated financial statements financial income expense financial income expense net expense million swiss francs net income equity securities million swiss francs increase interest income income debt securities decreased million swiss francs due shortterm interest rates remaining low levels major markets foreign exchange result mainly reflects hedging costs loss million swiss francs compared loss million swiss francs foreign exchange result included loss million swiss francs following devaluation venezuelan bolivar february million swiss francs losses hedges groups euroswiss franc position full analysis financial income expense given note consolidated financial statements details groups hedging arrangement given note income taxes groups effective core tax rate stable higher percentage core profit contribution coming tax jurisdictions relatively higher local tax rates average group rate notably us increased effective tax rate mostly offset retrospective reenactment us research development tax credits january means results include whole year tax credits respect well tax credits tax benefit million swiss francs recorded noncore items compared tax benefit million swiss francs decrease primarily due lower underlying noncore expenses compared specifically global restructuring plans including intangible asset impairments well lower legal environmental costs full details groups income tax positions given note consolidated financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate mchf mchf mchf mchf groups effective tax rate core basis global restructuring plans goodwill intangible assets equity compensation plans groups effective tax rate ifrs basis financial position decrease net debt position mainly driven free cash flow billion swiss francs transactions equity hedge groups employee stock option programmes increased net debt billion swiss francs net pension liabilities decreased billion swiss francs due changes discount rates changes plan rules groups pension plans net tax assets increased mainly due deferred tax effect equity compensation plans increased due increase price underlying equity interest payable relates mostly bonds notes coupon payment dates march september decline due continued repayment underlying debt december group held financial longterm assets market value billion swiss francs consist mostly holdings biotechnology companies acquired context licensing transactions scientific collaborations roche finance report roche group financial reviewfree cash flow cash outflow treasury activities decreased billion swiss francs mostly due lower interest payments total taxes paid billion swiss francs increase constant exchange rates due higher tax payments us partially offset base effect settlement certain outstanding tax positions total dividends paid billion swiss francs increase billion swiss francs compared reflecting increase roche group dividend cash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow millions chf pharmaceuticals diagnostics corporate group operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow roche group financial review roche finance report operating free cash flow increased constant exchange rates billion swiss francs driven strong growth underlying operating business core operating profit growth increases net working capital mainly inventories capital expenditure property plant equipment investment intangible assets higher divisions increased cash generated business partly absorbed cash utilisation restructuring legal provisions cash outflow treasury activities decreased billion swiss francs mostly due lower interest payments total taxes paid billion swiss francs increase constant exchange rates due higher tax payments us partially offset base effect settlement certain outstanding tax positions total dividends paid higher due increase annual roche group dividend free cash flow billion swiss francs higher constant exchange rates mainly due increased operating free cash flow lower interest payments partly offset higher dividend payments group refined calculation free cash flow exclude impact employee stock options line peer group see details comparative free cash flow information restated accordingly net debt millions chf december cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow transactions equity instruments business combinations net divestments subsidiaries hedging collateral arrangements currency translation fair value movements change net debt period december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period roche finance report roche group financial reviewnet debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen pound sterling total us dollardenominated debt includes bonds notes denominated euros swiss francs pounds sterling swapped us dollars therefore financial statements economic characteristics equivalent us dollardenominated bonds notes net debt position group december billion swiss francs decrease billion swiss francs december decrease net debt mainly due free cash flow billion swiss francs described includes dividend payments billion swiss francs transactions equity hedge groups employee stock option programmes increased net debt billion swiss francs group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued currencies us dollar time collateral agreements entered derivative counterparties mitigate counterparty risk fair value derivative hedging instruments increased due strengthening euro us dollar cash collateral billion swiss francs received roche collateral balance relation hedges nonus dollardenominated bonds notes mainly sensitive foreign exchange rate us dollar euro also pound sterling currently collateral balance moves approximately million us dollars foreign exchange rates move simultaneously redemption repurchase bonds notes see note consolidated financial statements impact liquid funds impact net debt position full details groups marketable securities cash debt positions given notes consolidated financial statements pensions postemployment benefits postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans million swiss francs million swiss francs plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources roche group financial review roche finance report defined benefit plans expenses groups defined benefit plans million swiss francs million swiss francs decrease mainly due past service income million swiss francs settlement income million swiss francs described partially offset increase current service cost million swiss francs driven lower discount rates beginning compared beginning expenses take account implementation ias revised increased net interest cost pensions million swiss francs approximately amount based revised actuarial assumptions end expenses groups defined benefit plans expected approximately million swiss francs estimates pension expenses include settlement past servicecurtailment effects might arise year operating income million swiss francs recorded past service costs changes groups pension plans switzerland uk germany represents onetime impact adjustment pension liability plan changes amount million swiss francs recorded pharmaceuticals division million swiss francs diagnostics division remaining million swiss francs income allocated corporate mainly attributable previously divested businesses addition us pension plans made offer deferred vested members settle part defined benefit obligation lump sum payment total lump sum payment made reduced plan assets million swiss francs settled million swiss francs defined benefit obligation resulting gain settlement million swiss francs funding status balance sheet position mchf mchf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability overall funding status ifrs basis groups defined benefit plans increased compared start year funding improvement mainly due reduction defined benefit obligation arising rise discount rates end comparison end changes groups plans referred also decreased defined benefit obligation million swiss francs plan assets remained stable company contributions increased million swiss francs compared million swiss francs settlement us plans reducing plan assets million swiss francs funded status pension funds monitored local pension fund governance bodies well closely reviewed group level addition cash injections group initiated plan changes several local pension plans described full details groups pensions postemployment benefits given note consolidated financial statements roche finance report roche group financial reviewroche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group consisting roche healthcare companies total shareholder return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange rates roche ranked number yearend return roche shares roche nonvoting equity securities combined performance share nonvoting equity security compared weighted average return peer group swiss franc terms constant exchange rates healthcare sector outperformed general market despite continued pricing pressure government budget constraints many parts world roche shares outperformed healthcare sector company achieved important new product approvals kadcyla breast cancer gazyva hematological cancers peer group abbott abbvie amgen astellas astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer roche sanofi takeda total shareholder return development dec march june sept dec roche share roche nonvoting equity security peer set index source datastream data roche peer index rebased january peer index converted chf daily actual exchange rates currency fluctuations influence representation relative performance roche versus peer index roche group financial review roche finance report proposed dividend board directors proposing increase dividend swiss francs per share nonvoting equity security swiss francs approval annual general meeting th consecutive increase dividend dividend proposal approved shareholders dividend payments total shares nonvoting equity securities amount billion swiss francs billion swiss francs resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security information roche securities given pages finance report information per share nonvoting equity security change chf chf chf eps basic eps diluted core eps basic core eps diluted equity attributable roche shareholders per share dividend per share details please refer notes consolidated financial statements finance report payout ratio calculated dividend per share divided core earnings per share payout ratio restated following accounting policy changes adopted roche finance report roche group financial reviewdebt finance genentech transaction group issued bonds notes equivalent billion swiss francs debt raised early already repaid december includes redemption billion eurodenominated notes due date march billion us dollars notes originally due march redeemed march following exercise early call option made december addition million us dollars notes originally due march redeemed august following exercise group early call option made june second half year group redeemed million swiss francs bonds due date september december group exercised option call early redemption billion us dollars notes due march notes repaid march maturity schedule groups bonds notes outstanding december shown table includes instruments already issue prior genentech transaction bonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc total total musd meur mgbp mchf musd mchf beyond total total translated december exchange rates following groups exercise early call option december billion us dollars notes originally due redeemed march five years ahead contractual maturity proceeds bonds notes billion euros swapped us dollars therefore financial statements bonds notes economic characteristics equivalent us dollardenominated bonds notes f proceeds bonds notes million pounds sterling swapped us dollars therefore financial statements bonds notes economic characteristics equivalent us dollardenominated bonds notes group plans meet debt obligations using existing liquid funds well cash generated business operations free cash flow billion swiss francs included cash generated operations well payment interest tax dividends shortterm financing requirements group commercial paper programme us issue billion us dollars unsecured commercial paper notes committed credit lines billion euros available backstop lines commercial paper notes totalling billion us dollars outstanding december billion us dollars longerterm financing group maintained strong longterm investmentgrade credit ratings aa standard poors moodys facilitate efficient access international capital markets credit ratings roche group december shortterm longterm outlook moodys p stable standard poors aa stable roche group financial review roche finance report financial risks december group net debt position billion swiss francs billion swiss francs financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt redemptions liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities mchf total mchf total cash cash equivalents money market instruments debt securities equity securities total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups billion swiss francs cash fixed income marketable securities remained strong invested aaaa range group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group trade receivables billion swiss francs since continuing financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries december trade receivables billion euros billion swiss francs public customers countries decrease compared december improved collections italy greece portugal spain remained stable compared group uses different measures improve collections countries including intense communication customers factoring negotiations payments plans charging interest late payments legal action group applying new commercial arrangements public hospitals greece portugal liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years roche strong longterm investmentgrade credit ratings aa standard poors moodys time roche rated highest available shortterm ratings agencies event financing requirements ratings strong credit roche permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling billion swiss francs billion swiss francs serve backstop line commercial paper programme december debt drawn credit lines market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes foreign exchange rates interest rates group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices groups var increased mainly due gradual increase longterm interest rates major economies roche finance report roche group financial reviewinterest rate risk interest rate risk arises movements interest rates could affect group financial result value group equity part groups hedging management group entered interest rate swap contracts combined notional principal billion us dollars swapped fixed interest rate effective floating interest rate months usdlibor plus average spread maturity swaps march period group entered interest rate swap contracts combined notional principal million swiss francs swapped fixed interest rate effective floating interest rate months chflibor plus average spread maturity swaps september information financial risk management financial risks var methodology included note consolidated financial statements international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since several new revised standards implemented effective january listed note consolidated financial statements except noted material impact groups overall results financial position amongst matters revised version ias employee benefits includes following changes existing standard e liminating option defer recognition actuarial gains losses defined benefit postemployment plans known corridor method group previously applied option rather uses option recognise gains losses comprehensive income option previously applied group henceforth requirement revised standard therefore change impact groups financial statements previous method including expected income plan assets estimated asset return replaced using discount rate used discount defined benefit obligation restated results causes reduction net financial income million swiss francs impact roches operating income net assets change p ast service costs recognised immediately income statement period plan amendment previously past service costs portion related unvested benefits deferred balance sheet progressively released information topic published investor update march available httpwwwrochecominvestorsirupdateinvupdatehtm group currently assessing potential impacts various new revised standards interpretations effective january beyond group yet applied based analysis date group anticipate material impact groups overall results financial position roche group financial review roche finance report roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statementsroche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf disclosed note income statement year ended december restated following accounting policy changes adopted reconciliation previously published income statement provided note roche group roche group consolidated financial statements roche finance report roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income remeasurements defined benefit plans items reclassified income statement availableforsale investments cash flow hedges currency translation foreign operations items may reclassified subsequently income statement comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total disclosed note statement comprehensive income year ended december restated following accounting policy changes adopted reconciliation previously published statement comprehensive income provided note roche finance report roche group roche group consolidated financial statementsroche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment goodwill intangible assets deferred tax assets defined benefit plan assets noncurrent assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred tax liabilities defined benefit plan liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity disclosed note balance sheets december december restated following accounting policy changes adopted reconciliation previously published balance sheets provided note roche group roche group consolidated financial statements roche finance report roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease net working capital payments made defined benefit plans utilisation provisions disposal products operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations divestment subsidiaries interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements equity contribution noncontrolling interests interest paid dividends paid equitysettled equity compensation plans net transactions equity financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december roche finance report roche group roche group consolidated financial statementsroche group consolidated statement changes equity millions chf non share retained fair value hedging translation controlling total capital earnings reserves reserves reserves total interests equity year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests equity contribution noncontrolling interests december disclosed note statement changes equity year ended december restated following accounting policy changes adopted reconciliation previously published total equity january provided note roche group roche group consolidated financial statements roche finance report notes roche group consolidated financial statements general accounting principles basis preparation consolidated financial statements hereafter annual financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except items required accounted fair value approved issue board directors january subject approval annual general meeting shareholders march financial statements annual financial statements roche holding ltd company registered switzerland subsidiaries group groups significant accounting policies changes accounting policies disclosed note key accounting judgements estimates assumptions preparation annual financial statements requires management make judgements estimates assumptions affect reported amounts revenues expenses assets liabilities contingent amounts actual outcomes could differ management estimates estimates underlying assumptions reviewed ongoing basis based historical experience various factors revisions estimates recognised period estimate revised following considered key accounting judgements estimates assumptions made believed appropriate based upon currently available information revenue nature groups business many sales transactions simple structure may consist multiple components occurring different times group also party outlicensing agreements involve upfront milestone payments occurring several years may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement may circumstances level sales returns hence revenues reliably measured cases sales recognised right return expires generally upon prescription products patients order estimate management uses publicly available information prescriptions well information provided wholesalers intermediaries roche finance report roche group notes roche group consolidated financial statementsat december group million swiss francs provisions accruals expected sales returns chargebacks rebates including medicaid us similar rebates countries estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience december group million swiss francs provisions doubtful receivables see note estimates based analyses ageing customer balances specific credit circumstances historical trends groups experience taking also account current economic conditions business combinations group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest consideration transferred business combination management judgement particularly involved recognition fair value measurement intellectual property contingent liabilities contingent consideration making assessment management considers underlying economic substance items concerned addition contractual terms impairment december group million swiss francs property plant equipment see note million swiss francs goodwill see note million swiss francs intangible assets see note goodwill intangible assets yet available use reviewed annually impairment property plant equipment intangible assets use assessed impairment triggering event provides evidence asset may impaired assess whether impairment exists estimates expected future cash flows used actual outcomes could vary significantly estimates discounted future cash flows factors changes discount rates planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence lower anticipated product sales could lead shorter useful lives impairment pensions postemployment benefits group operates number defined benefit plans fair value recognised plan assets liabilities based upon statistical actuarial calculations measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions december present value groups defined benefit obligation million swiss francs see note actuarial assumptions used may differ materially actual results due changes market economic conditions longer shorter life spans participants changes factors assessed differences could impact assets liabilities recognised balance sheet future periods legal provisions group provides anticipated legal settlement costs probable outflow resources reliably estimated december group million swiss francs legal provisions status significant legal cases disclosed note estimates consider specific circumstances legal case relevant legal advice inherently judgemental due highly complex nature legal cases estimates could change substantially time new facts emerge legal case progresses reliable estimate made provision recorded contingent liabilities disclosed material environmental provisions group provides anticipated environmental remediation costs probable outflow resources reasonably estimated december group million swiss francs environmental provisions see note environmental provisions consist primarily costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites estimates inherently judgemental due uncertainties related detection previously unknown contaminated sites method extent remediation percentage problematic materials attributable group remediation sites financial capabilities potentially responsible parties estimates could change substantially time new facts emerge environmental remediation progresses roche group notes roche group consolidated financial statements roche finance report income taxes december group current income tax net liability million swiss francs deferred tax net asset million swiss francs see note significant estimates required determine current deferred tax assets liabilities estimates based interpretations existing tax laws regulations factors may impact current deferred taxes include changes tax laws regulations rates changing interpretations existing tax laws regulations future levels research development spending changes pretax earnings leases treatment leasing transactions mainly determined whether lease considered operating finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments consolidation group periodically undertakes transactions may involve obtaining control significant influence companies transactions include equity acquisitions asset purchases alliance agreements transactions structured entities cases management makes assessment whether group control significant influence company whether consolidated subsidiary accounted associated company making assessment management considers underlying economic substance transaction addition contractual terms roche finance report roche group notes roche group consolidated financial statements operating segment information group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include corporate executive committee global group functions communications human resources finance including treasury taxes pension fund management legal safety environmental services subdivisional information roche pharmaceuticals chugai operating segments within pharmaceuticals division also presented divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs segment information depreciation property plant equipment amortisation intangible assets impairment reversal property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses roche group notes roche group consolidated financial statements roche finance report pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results operating profit elimination profit within division operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs elimination costs within division total segment information depreciation property plant equipment amortisation intangible assets impairment reversal property plant equipment impairment goodwill impairment intangible assets equity compensation plan expenses net operating assets millions chf assets liabilities net assets pharmaceuticals diagnostics corporate total operating nonoperating group disclosed note nonoperating net assets december december restated following accounting policy changes adopted reconciliation previously published balance sheet provided note roche finance report roche group notes roche group consolidated financial statementsnet operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets roche pharmaceuticals chugai elimination within division pharmaceuticals division information geographical area millions chf revenues external customers noncurrent assets royalties operating property plant goodwill sales income equipment intangible assets switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group notes roche group consolidated financial statements roche finance report supplementary unaudited information sales therapeutic areas pharmaceuticals division business areas diagnostics division given financial review sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue european union information based members eu december major customers total three us national wholesale distributors represent approximately quarter groups revenues three us national wholesale distributors amerisourcebergen corp billion swiss francs billion swiss francs mckesson corp billion swiss francs billion swiss francs cardinal health inc billion swiss francs billion swiss francs approximately revenues pharmaceuticals operating segment residual diagnostics segment net financial expense financing costs millions chf interest expense amortisation debt discount net gains losses redemption repurchase bonds notes discount unwind net interest cost defined benefit plans total financing costs financial income expense millions chf net gains losses sale equity securities net gains losses equity security derivatives dividend income writedowns impairments equity securities net income equity securities interest income net interest income income debt securities net foreign exchange gains losses net gains losses foreign currency derivatives foreign exchange gains losses net financial income expense associates total financial income expense roche finance report roche group notes roche group consolidated financial statementsnet financial expense millions chf financing costs financial income expense net financial expense financial result treasury management financial result pension management associates net financial expense disclosed note net financial expense year ended december restated following accounting policy changes adopted reconciliation previously published net financial expense provided note income taxes income tax expenses millions chf current income taxes deferred taxes total income tax expense disclosed note income tax expense year ended december restated following accounting policy changes adopted reconciliation previously published income tax expense provided note since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates groups average expected tax rate increased percentage points main driver increase due growth proportion groups profits generated us relatively higher local tax rate average group rate significant local tax rate changes main operating areas group compared groups effective tax rate increased main driver increase increase average expected tax rate explained partially offset retrospective reenactment us research development tax credits january means results include whole year tax credits respect well tax credits roche group notes roche group consolidated financial statements roche finance report groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development manufacturing tax credits us state tax impacts tax unremitted earnings utilisation previously unrecognised tax losses differences groups effective tax rate income tax benefits recorded respect equity compensation plans varies according price underlying equity million swiss francs million swiss francs income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefits approximately million swiss francs million swiss francs would recorded tax effects comprehensive income millions chf pretax aftertax pretax aftertax amount tax amount amount tax amount remeasurements defined benefit plans availableforsale investments cash flow hedges currency translation foreign operations comprehensive income income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred taxes assets liabilities net deferred tax assets liabilities roche finance report roche group notes roche group consolidated financial statementscurrent income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid charged credited income statement charged credited equity equity compensation plans transactions shareholders currency translation effects net current income tax asset liability december deferred taxes movements recognised net assets liabilities millions chf property plant intangible defined temporary equipment assets benefit plans differences total year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects december year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects december deferred tax assets temporary differences mainly relates accrued liabilities provisions unrealised profit inventory roche group notes roche group consolidated financial statements roche finance report deferred tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable mchf tax rate mchf tax rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred tax liabilities established withholding tax taxes would payable unremitted earnings foreign subsidiaries amounts currently regarded permanently reinvested total unremitted earnings group regarded permanently reinvested billion swiss francs december billion swiss francs business combinations acquisitions constitution medical investors inc july group acquired controlling interest constitution medical investors inc cmi us private company based massachusetts cmi developer highly innovative hematology testing system designed provide faster accurate diagnosis bloodrelated diseases helping improve patient care cmi reported diagnostics operating segment part professional diagnostics business area total consideration million us dollars million us dollars paid cash million us dollars arose contingent consideration arrangement contingent payments based achievement performancerelated milestones may arise end range undiscounted outcomes zero million us dollars identifiable assets acquired liabilities assumed set table acquisitions net assets acquired millions chf cmi intangible assets product intangibles available use deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash contingent consideration total consideration roche finance report roche group notes roche group consolidated financial statementsthe fair value intangible asset determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate valuation performed independent valuer goodwill represents control premium synergies obtained groups existing business none goodwill expected deductible income tax purposes directly attributable transaction costs million swiss francs reported diagnostics operating segment within general administration expenses impact cmi acquisition diagnostics division group reported results material acquisitions verum january group acquired controlling interest verum diagnostica gmbh verum german private company based munich verum reported diagnostics operating segment total consideration million euros million euros paid cash million euros arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero million euros identifiable assets acquired liabilities assumed set table acquisitions net assets acquired millions chf verum intangible assets product intangibles use inventories deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash contingent consideration total consideration cash flows business combinations acquisitions net cash outflow millions chf cash consideration paid cash acquired company contingent consideration paid total net cash outflow roche group notes roche group consolidated financial statements roche finance report global restructuring plans group continued implementation several major global restructuring plans initiated prior years notably reorganisation research development pharmaceuticals division programmes address longterm profitability diabetes care former applied science businesses diagnostics additionally income million swiss francs reversal previously incurred impairment charges bulk drug production unit vacaville site california global restructuring plans costs incurred millions chf diagnostics pharma rd plans total year ended december global restructuring costs employeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs year ended december global restructuring costs employeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs includes restructuring diabetes care former applied science business areas includes closure nutley site associated infrastructure environmental remediation costs includes operational excellence programme pharmaceuticals diagnostics dalcetrapib pharmaceuticals diagnostics division diabetes care applied science restructuring april group announced applied science business areas portfolio products integrated within business areas diagnostics division streamline decisionmaking enhance technology flow research use clinical setting september roche diabetes care announced autonomy speed initiative enable business focus diabetes care specific requirements speed processes decisionmaking drive efficiencies various initiatives announced diabetes care applied science businesses included increasing efficiency marketing distribution operations research development activities roche finance report roche group notes roche group consolidated financial statementsduring total costs million swiss francs million swiss francs incurred mainly headcount reductions itrelated costs site closure costs addition goodwill impairment charges million swiss francs incurred writeoff goodwill innovatis life sciences acquisitions former applied science business area intangible asset impairment charges million swiss francs also incurred related restructuring goodwill impairment charge million swiss francs incurred full writeoff goodwill nimblegen acquisition intangible asset impairment charges million swiss francs incurred pharmaceuticals division research development reorganisation june group announced streamlining research development activities within pharmaceuticals division planned operational closure us site nutley new jersey completed schedule end total costs million swiss francs incurred costs include million swiss francs employee related site closure costs year additional provisions million swiss francs cover site running costs expected divestment provisions mainly employeerelated costs property taxes outside services impairment million swiss francs carrying value nutley site based recent external property market data first results environmental investigations showed expected cost remediation may lower originally expected accordingly environmental provisions reduced million swiss francs total costs million swiss francs incurred mainly severance employeerelated costs property plant equipment impairments nutley site addition environmental remediation costs nutley site million swiss francs intangible asset impairment charges million swiss francs result portfolio prioritisation decisions linked reorganisation global restructuring plans october pharmaceuticals division announced part investments increase global biologic medicine manufacturing network capacity bulk drug production unit vacaville site california discontinued fully written put back service resulted income million swiss francs reversal previously incurred impairment charges see note costs million swiss francs million swiss francs incurred previously announced operational excellence programme mainly employeerelated site closure costs pharmaceuticals division employeerelated site closure costs diagnostics division sites burgdorf switzerland graz austria plans totalled million swiss francs million swiss francs also million swiss francs restructuring costs intangible asset impairment charges million swiss francs respect termination dalcetrapib daloutcomes trial studies dalheart programme roche group notes roche group consolidated financial statements roche finance report global restructuring plans summary costs incurred millions chf employeerelated costs termination costs defined benefit plans employeerelated costs total employeerelated costs site closure costs impairment reversal property plant equipment accelerated depreciation property plant equipment gains losses disposal property plant equipment site closure costs total site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs global restructuring plans classification costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics general administration pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total roche finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january additions disposals transfers depreciation charge impairment reversal charge currency translation effects december cost accumulated depreciation impairment net book value roche group notes roche group consolidated financial statements roche finance report impairment reversal charge october pharmaceuticals division announced details investments increase global biologic medicine manufacturing network capacity meet rising demand licensed biologics expected pipeline growth investments spread across sites penzberg germany basel switzerland well vacaville oceanside us bulk drug production unit vacaville site california yet licensed discontinued fully written part reassessment global manufacturing network requirements time bulk drug production unit vacaville site require capital investment become operational expected occur groups decision restart licensing efforts prepare operational use discontinued bulk drug production unit vacaville site commercial manufacturing resulted impairment reversal property plant equipment million swiss francs impairment reversal million swiss francs represents net book value time original impairment assets brought back use less depreciation would charged intervening period impairment occurred see note partly offset impairment million swiss francs carrying value nutley site based recent external property market data impairment charges mainly related property plant equipment nutley site classification impairment property plant equipment millions chf cost sales marketing distribution research development general administration total impairment reversal charge reimbursements received insurance companies respect impairments property plant equipment none borrowing costs capitalised property plant equipment none leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases million swiss francs million swiss francs net book value assets million swiss francs million swiss francs carrying value leasing obligation million swiss francs million swiss francs reported part debt see note finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value minimum payments lease payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted operating leases group companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense million swiss francs million swiss francs roche finance report roche group notes roche group consolidated financial statementsoperating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method finance leases future minimum lease receipts noncancellable leases millions chf present value gross investment lease minimum lease receipts within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments million swiss francs million swiss francs contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straightline basis december machinery equipment original cost million swiss francs million swiss francs net book value million swiss francs million swiss francs leased third parties contingent rents recognised income operating leases future minimum lease receipts noncancellable leases millions chf within one year one five years five years total minimum receipts capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs roche group notes roche group consolidated financial statements roche finance report goodwill goodwill movements carrying value assets millions chf january cost accumulated impairment net book value year ended december january business combinations impairment charge currency translation effects december cost accumulated impairment net book value allocated following cashgenerating units roche pharmaceuticals chugai total pharmaceuticals division diabetes care professional diagnostics molecular diagnostics applied science tissue diagnostics strategic goodwill held divisional level allocated business areas total diagnostics division impairment charge impairment charges totalling million swiss francs recorded related goodwill impairment charge million swiss francs recorded tissue diagnostics business area within diagnostics division impairment based latest business plans prepared second half main factors leading impairment reduced revenue expectations us following recent changes college american pathologists guidelines use negative reagent controls immunohistochemistry testing reduced volumes changes reduced reimbursement amount laboratories april group announced reorganisation applied science business area see note goodwill impairment charge million swiss francs incurred full writeoff goodwill life sciences acquisition innovatis acquisition former applied science business area goodwill impairment charge million swiss francs incurred full writeoff goodwill nimblegen acquisition see note roche finance report roche group notes roche group consolidated financial statementsimpairment testing pharmaceuticals division divisions subdivisions cashgenerating units used testing goodwill chugai recoverable amount based fair value less costs sell determined reference publicly quoted share prices chugai shares roche pharmaceuticals recoverable amount used impairment testing based value use cash flow projections used roche pharmaceuticals impairment testing based recent business plans approved management business plans include managements latest estimates sales volume pricing production operating costs assumes significant changes organisation business plans projected five years valuations include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data capital markets including government twentyyear bonds weighted average tax rate used calculations corresponding pretax discount rate diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division recoverable amount used impairment testing based value use cash flow projections based recent business plans approved management business plans include managements latest estimates sales volume pricing production operating costs assumes significant changes organisation business plans projected five years except tissue diagnostics business area projected ten years reflecting longterm nature business valuations include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data capital markets including government twentyyear bonds weighted average tax rate used calculations corresponding pretax discount rate sensitivity analysis management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount rate combined decreasing forecast cash flows chugai decreased publicly quoted share prices except tissue diagnostics business area results sensitivity analyses demonstrated changes key assumptions would cause carrying value goodwill exceed recoverable amount december key assumption changes would result goodwill impairment million swiss francs tissue diagnostics business area december roche group notes roche group consolidated financial statements roche finance report intangible assets intangible assets movements carrying value assets millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total january cost accumulated amortisation impairment net book value year ended december january business combinations additions transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group year ended december january business combinations additions transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group roche finance report roche group notes roche group consolidated financial statementssignificant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use tanox acquisition roche pharmaceuticals years corangeboehringer mannheim acquisition diagnostics years ventana acquisition diagnostics years product intangibles available use ventana acquisition diagnostics na cmi acquisition diagnostics na classification amortisation impairment expenses millions chf amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases december approximately projects pharmaceuticals division known decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project expected result commercialised product intangible asset impairment impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment roche group notes roche group consolidated financial statements roche finance report impairment charges pharmaceuticals division impairment charges totalling million swiss francs recorded related portfolio reassessment within hepatitis c virus hcv franchise million swiss francs assets concerned yet amortised written recoverable value million swiss francs portfolio reassessment within cardiovascular metabolic diseases franchise million swiss francs asset concerned yet amortised fully written decision stop two collaboration projects alliance partners million swiss francs assets concerned amortised fully written decision stop development one compound alliance partner million swiss francs asset concerned yet amortised fully written diagnostics division impairment charges totalling million swiss francs recorded applied science business area reorganisation see note assets concerned yet amortised fully written impairment charges pharmaceuticals division impairment charges totalling million swiss francs recorded related clinical data assessment project acquired part marcadia acquisition million swiss francs various global restructuring initiatives million swiss francs mainly related termination dalcetrapib trials see note portfolio prioritisation decisions million swiss francs mainly related return monoclonal antibody rg antiplgf mab alliance partners clinical data assessment two collaboration projects alliance partners million swiss francs decision stop development one compound alliance partner million swiss francs diagnostics division impairment charges totalling million swiss francs recorded mainly related applied science business area restructuring see note potential commitments alliance collaborations group party inlicensing similar arrangements alliance partners arrangements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration agreements groups current estimate future thirdparty commitments payments set table figures undiscounted risk adjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total roche finance report roche group notes roche group consolidated financial statements inventories inventories millions chf raw materials supplies work process intermediates finished goods less provision slowmoving obsolete inventory total inventories inventories expensed cost sales totalled billion swiss francs billion swiss francs inventory write downs year resulted expense million swiss francs million swiss francs accounts receivable accounts receivable millions chf trade receivables notes receivable receivables allowances doubtful accounts chargebacks allowances total accounts receivable allowances doubtful accounts movements recognised liability millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december bad debt reversal credited marketing distribution totalled million swiss francs expense million swiss francs roche group notes roche group consolidated financial statements roche finance report marketable securities marketable securities millions chf availableforsale financial assets equity securities debt securities money market instruments time accounts three months investments total marketable securities marketable securities held fund management purposes primarily denominated swiss francs us dollars euros money market instruments contracted mature within one year december debt securities contracted maturity millions chf within one year one five years five years total debt securities cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents roche finance report roche group notes roche group consolidated financial statements noncurrent assets noncurrent assets millions chf availableforsale investments held fair value availableforsale investments held cost loans receivable longterm trade receivables restricted cash receivables total financial noncurrent assets longterm employee benefits assets total nonfinancial noncurrent assets associates total noncurrent assets availableforsale investments mainly equity investments private biotechnology companies kept part groups strategic alliance efforts unquoted equity investments classified availableforsale measured cost fair value measured reliably current assets current assets millions chf accrued interest income derivative financial instruments restricted cash receivables total financial current assets prepaid expenses taxes recoverable assets total nonfinancial current assets total current assets receivables mainly related royalty licensing income receivables roche group notes roche group consolidated financial statements roche finance report accounts payable accounts payable millions chf trade payables taxes payable dividends payable payables total accounts payable noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities longterm liabilities mainly related accrued longterm employee benefits current liabilities current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued chargebacks allowances accrued royalties commissions accrued liabilities total current liabilities roche finance report roche group notes roche group consolidated financial statements provisions contingent liabilities provisions movements recognised liabilities millions chf legal environmental restructuring employee provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies contingent consideration currency translation effects december current noncurrent december year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies contingent consideration currency translation effects december current noncurrent december expected outflow resources within one year one two years two three years three years december legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies nature amounts timings outflows difficult predict legal expenses totalled million swiss francs million swiss francs reflect recent developments various legal matters details major legal cases outstanding disclosed roche group notes roche group consolidated financial statements roche finance report environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict significant provisions discounted time value money material significant provisions relate closure us site nutley new jersey estimated remediation costs landfill site near grenzach germany used manufacturing operations closed years ago increase million swiss francs estimated remediation costs landfill site near grenzach based latest remediation plan due submitted local authorities approval first results environmental investigations nutley showed expected cost remediation may lower originally expected accordingly environmental provisions reduced million swiss francs restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain provisions discounted time value money material matters significant provisions relate restructuring research development activities within pharmaceuticals division mainly related closure us site nutley new jersey restructuring diabetes care applied science businesses within diagnostics division employee provisions mostly relate certain employee benefit obligations sabbatical leave longservice benefits timings cash outflows reasonably estimated based past performance provisions timings cash outflows nature uncertain best estimates shown table provisions millions chf sales returns contingent consideration items total provisions contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note roche finance report roche group notes roche group consolidated financial statementspharmaceuticals legal cases accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions united states elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders december hlr defending approximately actions involving approximately plaintiffs brought various federal state courts throughout us personal injuries allegedly resulting use accutane actions allege ibd result accutane use hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product us actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation us district court middle district florida tampa division since july district court granted summary judgment favour hlr federal ibd cases proceeded since august rulings affirmed us court appeals eleventh circuit plaintiffs appealed multiple recently filed matters remain pending actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county december juries superior court ruled favour plaintiff eight cases assessing total compensatory damages totalling million us dollars ruled favour hlr four cases eight cases originally ruled favour plaintiff superior court hlr process appealing two cases million us dollars one case scheduled retrial january million us dollars posttrial briefing ongoing two cases million us dollars three cases verdicts reversed favour hlr million us dollars additional trials may scheduled individual trial results depend variety factors including many unique particular case therefore trial results date may predictive future trial results group continues defend vigorously remaining personal injury cases claims rituxan arbitration october genentech biogen idec inc filed complaint california sanofiaventis deutschland gmbh sanofi sanofiaventis us llc sanofiaventis us inc seeking declaratory judgment certain genentech products including rituxan infringe sanofis us patent nos patents invalid sanofi alleged rituxan another genentech product infringe certain claims patents march district court ruled matter law genentech biogen idec infringe asserted patent claims may sanofi appealed courts noninfringement ruling appellate court affirmed district courts judgment patent infringement addition october sanofi affiliate hoechst gmbh filed icc international court arbitration paris request arbitration genentech relating terminated patentlicense agreement one hoechsts predecessors genentech pertained abovementioned patents related patents outside us hoechst sought payment patentlicense royalties sales certain genentech products including rituxan damages breach contract relief various arbitral awards september february arbitrator found genentech liable hoechst patentlicense royalties rituxan awarded royalties interest hoechst sought february group recorded back royalty expense million swiss francs net assumed reimbursement portion groups obligation copromotion partner us corresponding amount accrued liabilities december accrued liability million swiss francs hoechst initiated proceedings us france germany seeking enforce arbitral awards october genentech paid awarded royalties interest hoechst protest genentech seeking annulment arbitral awards proceedings initiated court appeal paris hearing proceedings scheduled june outcome matter determined time roche group notes roche group consolidated financial statements roche finance report average wholesale prices litigation hlr roche laboratories inc rli along approximately brand generic pharmaceutical companies named defendants several legal actions us relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending one awp action filed state new jersey discovery currently pending case hlr rli vigorously defending matter outcome matter determined time pdl litigation august pdl biopharma pdl filed complaint nevada genentech seeking judicial declaration concerning genentechs obligation pay royalties certain exus sales herceptin avastin xolair lucentis agreement parties september pdl filed first amended complaint asserting additional claims genentech including breach contract breach implied covenant good faith fair dealing pdl also asserted new claims roche novartis intentional interference contractual relations addition declaratory relief pdl seeking monetary damages including compensatory liquidated damages november genentech roche filed motion dismiss failure state claim roche filed additional motion dismiss lack personal jurisdiction july court denied motions pdl settled claim novartis addition litigation pdl conducted royalty audit related sales avastin herceptin lucentis xolair raptiva years final audit report indicated pdls interpretation certain contract terms genentech owes pdl additional royalties audit period interpretation genentech may owe additional royalties years subsequent audit period group disputes pdls interpretation relevant contract terms believe additional royalties owed june pdl filed demand arbitration related audit claims american arbitration association parties stayed arbitration proceeding nevada litigation engaged discussions determine settlement certain issues possible gsk litigation september glaxosmithkline llc gsk genentech filed patent lawsuits one another delaware california respectively lawsuits concern gsks us patent nos gsk asserting claims genentech alleging infringement patents herceptin lucentis seeking compensatory damages lawsuit genentech seeking judicial declaration noninfringement invalidity patents june parties agreed dismiss california action without prejudice consolidated case proceeding delaware august delaware court issued claim construction order construing two terms patent trial scheduled june outcome matter determined time boniva litigation hlr genentech various roche affiliates collectively roche named defendants numerous legal actions us canada relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw atypical femoral fractures december roche defending approximately actions involving approximately plaintiffs brought federal state courts throughout us one action brought court queens bench province saskatchewan canada personal injuries allegedly resulting use boniva cases early discovery stages litigation individual trial results depend variety factors including many unique particular case roche vigorously defending matters outcome matters determined time roche finance report roche group notes roche group consolidated financial statementsema investigation october european medicines agency ema announced would start infringement procedure investigate allegations regarding alleged breach medicines safety reporting obligations relation centrally authorised medicines november ema announced results pharmacovigilance risk assessment committee assessment roches medicines ema found impact regarding benefitrisk balance roches medicines confirmed benefitrisk profiles based available safety information ema health authorities confirmed medicines remain authorised without changes treatment advice patients healthcare professionals corrective preventative actions resulting inspections implemented reinspection authorities november led certain findings roche addressing ema infringement procedure ongoing ema expected issue report eu commission april latest outcome investigation determined time diagnostics legal cases marsh supermarkets litigation july marsh supermarkets inc marsh filed breach contract suit roche diagnostics operations inc rdo lawsuit relates termination sublease agreement building rdo december hamilton superior court judge awarded marsh million us dollars provided april court appeals indiana upheld judgment october indiana supreme court declined hear appeal roche rdo paid final awarded damages interest million us dollars marsh matter concluded debt debt movements carrying value recognised liabilities millions chf january proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt net gains losses redemption repurchase bonds notes amortisation debt discount business combinations net foreign currency transaction gains losses currency translation effects december bonds notes commercial paper amounts due banks financial institutions finance lease obligations borrowings total debt longterm debt shortterm debt total debt pledges groups assets connection debt roche group notes roche group consolidated financial statements roche finance report bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollardenominated notes fixed rate notes due march principal billion us dollars isin usual usaq notes due march principal billion us dollars outstanding billion us dollars isin usuam usas notes due march principal billion us dollars isin usuan usau na european medium term note programme fixed rate notes due march principal billion euros isin xs notes due march principal billion pounds sterling outstanding billion pounds sterling isin xs notes due march principal billion euros outstanding billion euros isin xs notes due june principal billion euros isin xs na notes due march principal billion euros isin xs notes due august principal million pounds sterling outstanding million pounds sterling isin xs na swiss franc bonds floating rate notes due september principal billion swiss francs isin ch na swiss franc bonds fixed rate bonds due march principal billion swiss francs isin ch bonds due march principal billion swiss francs isin ch na bonds due september principal billion swiss francs isin ch bonds due september principal billion swiss francs isin ch na genentech senior notes senior notes due july principal billion us dollars isin usag na senior notes due july principal million us dollars isin usac na total bonds notes roche finance report roche group notes roche group consolidated financial statementsbonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds pound sterling notes total unamortised discount issuance bonds notes group issue bonds notes issuance bonds notes group raised net proceeds approximately billion swiss francs series debt offerings newly issued debt senior unsecured guaranteed roche holding ltd redemption repurchase bonds notes redemption eurodenominated notes due date march group redeemed fixed rate notes principal billion euros cash outflow million swiss francs plus accrued interest gain loss recorded redemption effective interest rate notes redemption us dollardenominated notes december group resolved exercise option call redemption entire outstanding us dollardenominated fixed rate notes due march march group redeemed remaining outstanding principal billion us dollars amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow million swiss francs plus accrued interest additional million swiss francs loss recorded redemption effective interest rate notes partial redemption us dollardenominated notes june group resolved exercise option call early partial redemption us dollardenominated fixed rate notes due march august group redeemed outstanding principal million us dollars amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow million swiss francs plus accrued interest million swiss francs loss recorded redemption effective interest rate notes redemption swiss francdenominated bonds due date september group redeemed floating rate bonds principal billion swiss francs cash outflow million swiss francs plus accrued interest gain loss recorded redemption effective interest rate notes roche group notes roche group consolidated financial statements roche finance report early redemption us dollardenominated notes december group resolved exercise option call early partial redemption us dollardenominated fixed rate notes due march group redeem outstanding principal billion us dollars march amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal us treasury rate determined independent investment banker third business day preceding redemption cash outflow approximately million us dollars plus accrued interest expected redemption group revised carrying value notes take account changes amounts timings estimated cash flows revised carrying value notes december million us dollars million swiss francs increase carrying value million us dollars million swiss francs recorded within financing costs see note loss redemption effective interest rate notes redemption repurchase bonds notes group redeemed billion swiss francs bonds due date completed tender offer repurchase billion euros notes billion swiss francs exercised option call early redemption billion us dollars notes march cash flows issuance redemption repurchase bonds notes cash inflows issuance bonds notes millions chf european medium term note programme eurodenominated notes swiss francdenominated bonds total cash inflows issuance bonds notes cash outflows redemption repurchase bonds notes millions chf european medium term note programme eurodenominated notes us dollardenominated notes swiss francdenominated bonds total cash outflows redemption repurchase bonds notes commercial paper roche holdings inc commercial paper program roche holdings inc established commercial paper program issue billion us dollars unsecured commercial paper notes guaranteed roche holding ltd committed credit line billion euros available backstop line maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount million us dollars average interest rate outstanding movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december roche finance report roche group notes roche group consolidated financial statementsamounts due banks financial institutions amounts denominated various currencies notably chinese renminbi argentine pesos average interest rate amounts outstanding million swiss francs december due within one year equity attributable roche shareholders changes equity attributable roche shareholders millions chf reserves share retained fair capital earnings value hedging translation total year ended december january net income recognised income statement availableforsale investments fair value gains losses taken equity transferred income statement income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity december disclosed note reserves december december restated following accounting policy changes adopted reconciliation previously published reserves provided note entire amount transferred income statement reported financial income expense roche group notes roche group consolidated financial statements roche finance report changes equity attributable roche shareholders millions chf reserves share retained fair capital earnings value hedging translation total year ended december january net income recognised income statement availableforsale investments fair value gains losses taken equity transferred income statement income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity december entire amount transferred income statement reported financial income expense genentech transaction group completed purchase noncontrolling interests genentech effective march based international accounting standard separate financial statements ias consistent international financial reporting standard consolidated financial statements ifrs adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group time reduced billion swiss francs billion swiss francs allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacted groups net equity effect groups business dividend policy roche finance report roche group notes roche group consolidated financial statementsshare capital december authorised issued share capital roche holding ltd groups parent company consisted million shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool described note based information supplied group novartis ltd basel affiliates participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend swiss francs per share nonvoting equity security swiss francs respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board directors proposed dividends business year swiss francs per share nonvoting equity security approved would result total distribution shareholders million swiss francs subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities millions millions shares nonvoting equity securities derivative instruments total roche group notes roche group consolidated financial statements roche finance report equity instruments recorded within equity original purchase cost details equity instruments held december shown table fair values disclosed information purposes equity instruments december supplementary information equivalent number nonvoting strike price market value equity securities millions maturity chf chf billions shares nonvoting equity securities jan derivative instruments feb total equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note derivative instruments mainly consist call options exercisable time maturity reserves fair value reserve fair value reserve represents cumulative net change fair value availableforsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai consolidated subsidiary chugai fully consolidated subsidiary group based groups interest chugai december roche relationship chugai founded basic alliance licensing research collaboration agreements common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements accordance international financial reporting standards ifrs filed quarterly basis tokyo stock exchange due certain consolidation entries minor differences chugais standalone ifrs results results chugai consolidated roche group accordance ifrs roche finance report roche group notes roche group consolidated financial statementsfinancial information chugai summarised financial information millions chf income statement sales royalties operating income total revenues operating profit balance sheet noncurrent assets current assets noncurrent liabilities current liabilities total net assets cash flows cash flows operating activities cash flows investing activities cash flows financing activities dividends dividends distributed third parties holding chugai shares totalled million swiss francs million swiss francs recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also right first refusal development marketing japan development compounds advanced roche roche group notes roche group consolidated financial statements roche finance report rest world umbrella rights agreement signed may roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea chugai decides requires partner activities agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas smallmolecule synthetic drug research biotechnologybased drug discovery noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement chugai noncontrolling interests total net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans comprehensive income net tax total comprehensive income dividends noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity changes noncontrolling interests equity contribution noncontrolling interests december chugai noncontrolling interests total noncontrolling interests disclosed note noncontrolling interests year ended december restated following accounting policy changes adopted reconciliation previously published noncontrolling interests provided note roche finance report roche group notes roche group consolidated financial statements employee benefits employee remuneration millions chf wages salaries social security costs defined contribution plans operating expenses defined benefit plans equity compensation plans termination costs employee benefits employee remuneration included operating results net interest cost defined benefit plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits pensions postemployment benefits disclosed note following implementation ias revised group amended accounting policy respect pensions postemployment benefits restated related comparatives disclosures groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups long term financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans defined contribution plans defined contribution plans funded payments employees group funds administered third parties groups expenses plans million swiss francs million swiss francs assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions groups major defined contribution plans united states notably us roche k savings plan roche group notes roche group consolidated financial statements roche finance report defined benefit plans plans usually established trusts independent group funded payments group companies employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources plans usually governed senior governing body board trustees typically composed employee employer representatives funding plans determined local regulations using independent actuarial valuations separate independent actuarial valuations together semiannual update prepared accordance requirements ias use groups financial statements groups major defined benefit plans located switzerland us germany total account groups defined benefit obligation pension plans switzerland current pension arrangements employees switzerland made plans governed swiss federal occupational old age survivors disability pension act bvg groups pension plans administered separate legal foundations funded regular employee company contributions final benefit contributionbased certain minimum guarantees due minimum guarantees swiss plans treated defined benefit plans purposes ifrs financial statements although many characteristics defined contribution plans underfunding may remedied various measures increasing employee company contributions lowering interest rate retirement account balances reducing prospective benefits suspension early withdrawal facility past service costs include million swiss francs income recorded respect changes groups pension plans switzerland change represents adoption lower conversion rates determines annuity normal retirement age pension plans united states groups major defined benefit plans us closed new members since new employees us join defined contribution plan largest remaining defined benefit plans funded pension plans including separate plans originating nutley palo alto indianapolis sites together smaller unfunded supplementary retirement plans benefits based highest average annual rate earnings specified period length employment plans noncontributory employees group making periodic payments plans payments made group million us dollars million us dollars underfunding would normally remedied additional company contributions us pension plans made offer deferred vested members settle defined benefit obligation lump sum payment total lump sum payment made defined benefit assets million us dollars million swiss francs settled obligation million us dollars million swiss francs led gain million us dollars million swiss francs included settlement gain past service costs include million swiss francs income recorded respect curtailments us defined benefit plans arose primarily reorganisation pharmaceuticals divisions research development organisation involved closure site nutley new jersey pension plans germany groups major pension arrangements germany governed occupational pensions act betravg plans unfunded group pays pensions retired employees directly financial resources plans noncontributory employees benefits based final salary length employment plans closed new members since replaced new plan funded regular employee company contributions administered contractual trust agreement final benefit contributionbased minimum guarantee due minimum guarantee plan treated defined benefit plan purposes ifrs financial statements although many characteristics defined contribution plan past service costs include million swiss francs income recorded respect changes groups german pension plans change represents adoption increase normal retirement age roche finance report roche group notes roche group consolidated financial statementspension plans rest world represent approximately groups defined benefit obligation consist number smaller plans various countries largest pension plans chugai independently managed chugai main pension plan united kingdom chugai plans fully described chugais ifrs financial statements uk pension plan funded regular employee company contributions benefits based final salary length employment plan closed new members since replaced defined contribution plan past service costs include million swiss francs income recorded respect changes groups uk pension plans reflects change indexation pension increases consumer price index instead previously used retail price index postemployment benefit opeb plans represent approximately groups defined benefit obligation consist mostly postretirement healthcare life insurance schemes mainly us plans mainly unfunded contributory employees group reimbursing retired employees directly financial resources groups major defined benefit opeb plans us closed new members since part costs plans reimbursable medicare prescription drug improvement modernization act statutory funding requirement plans group funding plans extent tax efficient payments made group plans none december ifrs funding status including reimbursement rights funded opeb plans us defined benefit plans income statement millions chf post post pension employment total pension employment total plans benefit plans expense plans benefit plans expense current service cost past service income cost settlement gain loss total operating expenses net interest cost defined benefit plans total expense recognised income statement funding status funding groups various defined benefit plans responsibility senior governing body board trustees sponsoring employer managed based local statutory valuations follow legislation requirements respective jurisdiction plan established qualified independent actuaries carry statutory actuarial valuations regular basis actuarial assumptions determining funding status statutory basis regularly assessed local senior governing body funding status closely monitored corporate level fair value plan assets increased due favourable market conditions higher discount rates compared changes pension plans switzerland germany uk described resulted decrease overall defined benefit obligation result ifrs funded status funded defined benefit plans improved reimbursement rights linked postemployment medical plans us represent expected reimbursement medical expenditure provided medicare prescription drug improvement modernization act roche group notes roche group consolidated financial statements roche finance report defined benefit plans funding status millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability reported balance sheet defined benefit plan assets defined benefit plan liabilities plan assets responsibility investment strategies funded plans senior governance body board trustees assetliability studies performed regularly major pension plans studies examine obligations postretirement benefit plans evaluate various investment strategies respect key financial measures expected returns expected risks expected contributions expected funded status plan interdependent way goal assetliability study select appropriate asset allocation funds held within plan investment strategy developed optimise expected returns manage risks contain fluctuations statutory funded status assetliability studies include strategies match cash flows assets plan obligations group currently use annuities longevity swaps manage longevity risk plan assets managed using internal external asset managers actual performance continually monitored pension fund governance bodies well closely monitored corporate level financial statements difference interest income actual return plan assets remeasurement recorded directly comprehensive income actual return plan assets gain million swiss francs gain million swiss francs recognition pension assets limited present value economic benefits available refunds plans reductions future contributions plans roche finance report roche group notes roche group consolidated financial statementsdefined benefit plans fair value plan assets reimbursement rights millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january interest income plan assets remeasurements plan assets currency translation effects employer contributions employee contributions benefits paid funded plans benefits paid settlements past service income cost administration costs december defined benefit plans composition plan assets millions chf equity securities debt securities property cash money market instruments investments december assets invested variety different classes order maintain balance risk return follows equity debt securities mainly quoted market prices level fair value hierarchy property mainly private commercial property funds quoted market prices level fair value hierarchy directly held property investments level fair value hierarchy cash money market instruments mainly invested financial institutions credit rating lower investments mainly consist alternatives mortgages commodities used risk management purposes mainly quoted market price level fair value hierarchy included within fair value plan assets groups shares nonvoting securities fair value million swiss francs million swiss francs debt instruments issued group fair value million swiss francs million swiss francs swiss pension plans purchased million roche shares group million swiss francs roche group notes roche group consolidated financial statements roche finance report defined benefit obligation defined benefit obligation calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth mortality rates present value defined benefit obligation determined discounting estimated future cash outflows using interest rates highquality corporate bonds government bonds countries deep market corporate bonds corporate government bonds denominated currency benefits paid maturity terms approximating terms related pension obligation groups final salarybased defined benefit pension plans us germany united kingdom closed new participants active employees members pension plans time closed new participants continue accrue benefits final salarybased defined benefit pension plans new employees us uk join groups defined contribution plans new employees germany join contributionbased plan minimum guarantee defined benefit pension plans switzerland final benefit contribution based minimum guarantee remain open new employees result proportion defined benefit obligation relates closed plans expected decrease future defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost remeasurements demographic assumptions financial assumptions experience adjustments currency translation effects employee contributions benefits paid funded plans benefits paid unfunded plans benefits paid settlements past service income cost settlement gain loss december composition plan active members deferred vested members retired members december plans geography switzerland united states germany rest world december duration years roche finance report roche group notes roche group consolidated financial statementsactuarial assumptions actuarial assumptions used financial statements based requirements set ias employee benefits unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management based advice actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates salary benefit levels inflation rates costs medical benefits actuarial assumptions vary based upon local economic social conditions actuarial assumptions used various statutory valuations may differ based local legal regulatory requirements demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity rates employee turnover disability early retirement based historical behaviour within group companies average life expectancy assumed individual age follows defined benefit plans average life expectancy major schemes years male female country mortality table switzerland bvg generational tables united states rp projected germany heubeck tables g financial assumptions based market expectations period obligations settled assumptions used actuarial valuations shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates determined reference interest rates highquality corporate bonds government bonds countries deep market corporate bonds expected rates salary increases based expected inflation rates adjustment reflect groups latest expectation longterm real salary increases expected rates pension increases generally linked expected inflation rate expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances medical cost trend rates take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments us roche group notes roche group consolidated financial statements roche finance report sensitivity analysis measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions following table summarises impact change assumptions present value defined benefit obligation defined benefit plans sensitivity defined benefit obligation actuarial assumptions millions chf year increase life expectancy discount rates increase decrease expected inflation rates increase decrease immediate medical cost trend rate increase decrease sensitivity analysis considers change one assumption time leaving assumptions unchanged approach shows isolated effect changing one individual assumption take account assumptions related method used carry sensitivity analysis prior year cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately million swiss francs includes estimated million swiss francs additional contributions mostly related us defined benefit plans benefits paid unfunded plans estimated approximately million swiss francs mostly relate german defined benefit plans roche finance report roche group notes roche group consolidated financial statements equity compensation plans group operates several equity compensation plans including separate plans chugai ifrs sharebased payment requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses equity compensation plans roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan roche connect roche option plan bonus stock awards chugai stock acquisition rights total operating expenses equitysettled cashsettled cash inflow outflow equity compensation plans millions chf roche option plan exercises chugai stock acquisition rights exercises roche connect costs transactions equity total cash inflow outflow equitysettled equity compensation plans net transactions equity net cash outflow transactions equity mainly arises sales purchases equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note roche group notes roche group consolidated financial statements roche finance report equity compensation plans roche stocksettled stock appreciation rights group issues stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date ssar plan regulations restated amended effective january referred roche ssar plan roche ssar plan million ssars available issuance tenyear period rights nontradable equitysettled awards sevenyear duration vest phased basis three years roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance conditions currently performance conditions outstanding rsus december rsu plan regulations restated amended effective january referred roche rsu plan roche rsu plan million nonvoting equity securities available issuance tenyear period roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted roche finance report roche group notes roche group consolidated financial statementsroche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december vested transferable roche performance share plan group offers future nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers nontradable equity settled awards programme currently operates annual threeyear cycles roche performance share plan regulations restated amended effective january referred roche psp plan roche psp plan includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted amount nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors award result zero two nonvoting equity securities value adjustment depending upon achievement performance targets roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years years allocated recipients feb feb feb fair value per unit grant chf total fair value grant chf millions roche connect programme enables employees worldwide except us certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million cost plan million swiss francs million swiss francs roche option plan programme used countries ssars used awards plan give employees right purchase nonvoting equity securities exercise price specified grant date roche option plan regulations restated amended effective january referred roche option plan options nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment roche group notes roche group consolidated financial statements roche finance report roche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands contractual life chf thousands chf total weighted average share price roche nonvoting equity securities year swiss francs swiss francs bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair value per award calculated grant date chugai stock acquisition rights chugai stock acquisition right programmes total fair value rights issued equivalent million swiss francs million swiss francs rights issued employees directors chugai rights nontradable equitysettled awards tenyear duration vest two years right entitles holder purchase chugai shares specified exercise price addition rights issued directors chugai thirtyyear duration vest upon holders retirement director chugai right entitles holder purchase chugai shares exercise price japanese yen roche finance report roche group notes roche group consolidated financial statementsfair value measurement inputs used measurement fair values grant date equity compensation plans follows fair value measurement roche stocksettled roche stock appreciation roche restricted performance share roche option rights stock unit plan plan plan progressively cliff vesting cliff vesting progressively vesting period years years years years contractual life years na na years number granted year weighted average fair value chf model used binomial market price monte carlo b binomial inputs option pricing model share price grant date chf exercise price chf expected volatility c na na expected dividend yield na na early exercise factor na na expected exit rate na na fair value roche rsus equivalent share price date grant b input parameters covariance matrix roche individual companies peer group based threeyear history risk free rate minus valuation takes account defined rank performance structure determines payout plan c volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour earnings per share nonvoting equity security basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number shares nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf roche group notes roche group consolidated financial statements roche finance report diluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf disclosed note earnings per share nonvoting equity security year ended december restated following accounting policy changes adopted reconciliation previously published earnings per share nonvoting equity security provided note statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense financing costs financial income expense income taxes operating profit depreciation property plant equipment amortisation intangible assets impairment goodwill impairment intangible assets impairment reversal property plant equipment operating income expense defined benefit plans operating expense equitysettled equity compensation plans net income expense provisions bad debt reversal expense inventory writedowns adjustments cash generated operations disclosed note net income nonoperating income expense year ended december restated following accounting policy changes adopted reconciliation previously published net income nonoperating income expense provided note roche finance report roche group notes roche group consolidated financial statementscash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity dividends paid millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai dividends noncontrolling shareholders dividend withholding tax total significant noncash transactions significant noncash transactions none risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part business planning controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties roche group notes roche group consolidated financial statements roche finance report financial risk management within group governed policies reviewed boards directors roche chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets accounts receivable december group trade receivables billion swiss francs billion swiss francs subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective trade receivables management maximise collection unpaid amounts december groups combined trade receivables balance three us national wholesale distributors amerisourcebergen corp mckesson corp cardinal health inc equivalent billion swiss francs representing groups consolidated trade receivables billion swiss francs representing significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held trade receivables none since financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries trade receivables billion swiss francs billion swiss francs public customers countries december trade receivables italy greece portugal decreased due improved collections spain remained stable compared group uses different measures improve collections countries including intense communication customers factoring negotiations payments plans charging interest late payments legal action nature geographic location counterparties accounts receivable overdue impaired shown table include balances us national wholesalers southern europe public customers described accounts receivable overdue nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland europe north america latin america japan asia australia oceania rest world total roche finance report roche group notes roche group consolidated financial statementsthe ageing accounts receivable impaired shown table ageing accounts receivable impaired millions chf neither overdue impaired overdue month overdue months overdue months overdue months overdue year total accounts receivable cash marketable securities december group cash marketable securities billion swiss francs billion swiss francs subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity cash shortterm time deposits subject rules limit groups exposure individual financial institutions rating analysis cash fixed income marketable securities market values mchf total mchf total aaarange aarange arange bbbrange bbbrange unrated total master netting agreements group enters derivative transactions collateral agreements international swaps derivatives association isda master netting agreements respective counterparties order mitigate counterparty risk agreements amounts owed counterparty single day respect transactions outstanding currency aggregated single net amount payable one party isda agreements meet criteria offsetting balance sheet group currently enforceable right offset recognised amounts right offset enforceable occurrence future events default credit events contract terms december significant financial assets whose terms renegotiated none impairment losses total impairment losses availableforsale financial assets amounted million swiss francs million swiss francs roche group notes roche group consolidated financial statements roche finance report liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements december group unused committed credit lines various financial institutions totalling billion swiss francs billion swiss francs billion swiss francs serve backstop line commercial paper programme remaining undiscounted cash flow contractual maturities financial liabilities including estimated interest payments shown table contractual maturities financial liabilities millions chf carrying less value total year years years years year ended december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities year ended december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities market risk market risk arises changing market prices mainly foreign exchange rates interest rates groups financial assets financial liabilities affect groups financial result equity valueatrisk group uses valueatrisk var measure impact market risk financial instruments var indicates value range within given financial instrument fluctuate preset probability result movements market prices var calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate actual future gains losses associated treasury activities may differ materially var analyses due inherent limitations associated predicting timing amount changes interest rates foreign exchange rates equity investment prices particularly periods high market volatilities furthermore var include effect changes credit spreads roche finance report roche group notes roche group consolidated financial statementsmarket risk financial instruments millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component increased mainly due gradual increase longterm interest rates major economies foreign exchange component decreased due favourable exposure mix price component arises mainly movements equity security prices remained largely stable foreign exchange risk group uses swiss franc reporting currency result exposed movements foreign currencies mainly us dollar japanese yen euro objective groups foreign exchange risk management activities preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates interest rate risk group mainly raises debt fixed rate basis bonds notes group exposed movements interest rates mainly us dollar swiss franc eurodenominated floating rate financial instruments primary objective groups interest rate management protect net interest result group may use forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures interest rate hedging group entered following interest rate hedging contracts interest rate swap contracts combined notional principal billion us dollars swapped fixed interest rate effective floating interest rate months usdlibor plus average spread maturity swaps march interest rate swap contracts combined notional principal million swiss francs swapped fixed interest rate effective floating interest rate months chflibor plus average spread maturity swaps september price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments roche group notes roche group consolidated financial statements roche finance report capital management group defines capital manages groups total capitalisation sum debt plus equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events capitalisation reported senior management part groups regular internal management reporting shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation disclosed note total equity december december restated following accounting policy changes adopted reconciliation previously published total equity provided note groups net equity significantly impacted genentech transaction see note group subject regulatory capital adequacy requirements known financial services industry group majority shareholding chugai see note chugai public company objectives policies processes managing capital determined local management roche finance report roche group notes roche group consolidated financial statementsfinancial instrument accounting classifications fair values fair values financial assets liabilities together carrying value shown consolidated balance sheet follows carrying value fair value financial instruments millions chf fair value loans total available hedging fair value financial carrying forsale instruments designated receivables liabilities value fair value year ended december noncurrent assets availableforsale investments financial noncurrent assets accounts receivable marketable securities cash cash equivalents current assets derivative financial instruments financial currents assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities year ended december noncurrent assets availableforsale investments financial noncurrent assets accounts receivable marketable securities cash cash equivalents current assets derivative financial instruments financial currents assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities fair value bonds notes calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods roche group notes roche group consolidated financial statements roche finance report fair value hierarchy table analyses financial instruments carried fair value valuation method different levels defined follows level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial instruments millions chf level level level total year ended december marketable securities equity securities debt securities money market instruments time accounts three months derivative financial instruments availableforsale investments held fair value financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value year ended december marketable securities equity securities debt securities money market instruments time accounts three months derivative financial instruments availableforsale investments held fair value financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments group determines level fair values using following valuation techniques marketable securities derivative financial instruments based valuation models use observable market data interest rates yield curves foreign exchange rates implied volatilities similar instruments measurement date availableforsale investments using valuation model derived recently published observable financial prices group recognises transfers levels fair value hierarchy end reporting period transfer occurred significant transfers level level vice versa year none roche finance report roche group notes roche group consolidated financial statementslevel fair values details determination level fair value measurements transfer level fair value hierarchy set contingent consideration arrangements millions chf january arising business combination total unrealised gains losses included income statement unused amounts reversed additional amount created discount unwind total gains losses included comprehensive income currency translation effects transfers level utilised december contingent consideration arrangements group party certain contingent consideration arrangements arising business combination arrangements fair value determined considering expected payment discounted present value using riskadjusted discount rate expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario significant unobservable inputs forecast sales performance criteria riskadjusted discount rate estimated fair value would increase forecast sales performance criteria rate higher riskadjusted discount rate lower december payments contingent consideration arrangements could million swiss francs derivative financial instruments group entered various currency swaps certain nonus dollar debt instruments cash collateral agreements entered counterparties currency swaps mitigate counterparty risk following table sets carrying value derivative financial instruments amounts subject master netting agreements derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives carrying value derivative financial instruments derivatives subject master netting agreements collateral arrangements net amount roche group notes roche group consolidated financial statements roche finance report collateral arrangements fair value currency swaps increased mainly due stronger euro compared us dollar result cash delivered group counterparties movements cash collateral receivable accrued liability millions chf january net cash delivered group december hedge accounting december group following cash flow hedges fair value hedges designated qualifying hedge relationship cash flow hedges group entered crosscurrency swaps hedge foreign exchange interest rate risk bonds notes issued group denominated euros sterling december instruments recorded fair value assets million swiss francs assets million swiss francs ineffective portion group entered foreign exchange forward contracts hedge part foreign translation exposure euros remaining foreign exchange forward contracts matured resulting loss million swiss francs recorded income statement december instruments recorded fair value liabilities million swiss francs chugai entered foreign exchange forward contracts hedge part foreign translation exposure swiss francs us dollars december instruments recorded fair value assets million swiss francs assets million swiss francs ineffective portion expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table expected cash flows qualifying cash flow hedges millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity expected cash flows qualifying cash flow hedges impact profit loss millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow roche finance report roche group notes roche group consolidated financial statementsthe changes hedging reserve within equity shown note fair value hedges group entered interest rate swaps hedge fixedterm debt instruments december instruments recorded fair value liabilities million swiss francs fair value assets million swiss francs assets million swiss francs loss million swiss francs recorded interest rate swaps loss million swiss francs fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments group equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure group entered forward contracts designated qualify fair value hedges december instruments recorded fair value liabilities million swiss francs liabilities million swiss francs loss million swiss francs recorded forward contracts loss million swiss francs result forward contracts offset changes fair value hedged equity investments net investment hedges group net investment hedges related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalski hoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received remuneration totalling swiss francs swiss francs dr oeri received remuneration totalling swiss francs swiss francs transactions group individual members shareholder group subsidiaries associates listing major group subsidiaries associates included note transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates key management personnel total remuneration key management personnel million swiss francs million swiss francs million swiss francs members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees total remuneration board directors excluding chairman chief executive officer totalled million swiss francs million swiss francs million swiss francs roche group notes roche group consolidated financial statements roche finance report chairman board directors members corporate executive committee roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee chairman board directors members corporate executive committee also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members corporate executive committee mr diggelmann dr hippe included table full calendar year joined cec similarly members corporate executive committee retiring part way year dr soriot dr hunziker included full calendar year left cec remuneration chairman board directors members corporate executive committee millions chf salaries including cashsettled bonus bonus stock awards social security costs pensions postemployment benefits equity compensation plans retirement awards employee benefits total purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included financial statements roche holding ltd basel pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration chairman board directors members corporate executive committee ifrs basis see table deduct bonus stock awards ifrs basis equity compensation plans ifrs basis add back bonus stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration chairman board directors members corporate executive committee swiss legal basis chairman board directors members corporate executive committee roche finance report roche group notes roche group consolidated financial statementsbonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair value per award calculated grant date equity compensation plans chairman board directors members corporate executive committee received equity compensation shown following tables number rights options awards granted corporate executive committee roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan contributions paid chairman board directors corporate executive committee millions chf roche connect transactions former members corporate executive committee pensions totalling million swiss francs paid group former corporate executive committee members million swiss francs million swiss francs defined benefit plans transactions group various defined benefit plans employees group described note subsidiaries associates listed companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy roche group notes roche group consolidated financial statements roche finance report nonlisted companies share capital equity interest country company city millions algeria roche algrie spa bab ezzouar dzd argentina productos roche sa qumica e industrial buenos aires ars vanguardia en productos farmacuticos buenos aires ars vanprofarma sa australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur roche diagnostics graz gmbh graz eur azerbaijan roche azerbaijan llc baku azn bangladesh roche bangladesh limited dhaka bdt belarus fllc roche products limited minsk byr belgium nv roche sa brussels eur roche diagnostics belgium nv brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche china holding ltd shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostics hvidovre dkk dominican republic productos roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc egypt ropharm limited cairo egp estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france institut roche de recherche et mdecine translationnelle sas boulognebillancourt eur roche diagnostics france sas meylan eur roche sas boulognebillancourt eur ventana medical systems sas illkirch eur georgia roche georgia llc tbilisi gel roche finance report roche group notes roche group consolidated financial statementsshare capital equity interest country company city millions germany galenus mannheim gmbh mannheim eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen eur roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche mtm laboratories ag heidelberg eur roche pharma ag grenzachwyhlen eur roche pvt gmbh waiblingen dem swisslab gmbh berlin eur verum diagnostica gmbh munich eur ghana roche products ghana limited accra ghs greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche products india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr iran roche pars co ltd tehran irr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd petach tikva ils italy roche diagnostics spa milan eur roche spa milan eur ivory coast roche cte divoire sarl abidjan xof japan roche diagnostics kk tokyo jpy kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga lvl lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius lit macedonia roche makedonija dooel skopje mkd malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd petaling jaya myr syntex pharmaceuticals sdn bhd kuala lumpur myr mauritius roche products mauritius limited quatre bornes mur mexico productos roche sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn moldova roche products limited srl chisinau mdl morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherlands roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche products limited lagos ngn norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd panama productos roche panam sa panama city pab productos roche interamericana sa panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd roche group notes roche group consolidated financial statements roche finance report share capital equity interest country company city millions peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc taguig city php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostics rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche doo pharmaceutical company ljubljana eur south africa roche products proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sri lanka roche products colombo private limited colombo lkr sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland f hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabetes care ltd burgdorf chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah united arab emirates roche diagnostics middle east fzco dubai aed roche middle east fzco dubai aed united kingdom piramed limited welwyn garden city gbp roche diagnostics ltd burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp roche finance report roche group notes roche group consolidated financial statementsshare capital equity interest country company city millions united states life sciences corporation branford usd alios biopharma inc south san francisco usd anadys pharmaceuticals inc south san francisco usd bioveris corporation indianapolis usd genentech inc south san francisco usd genentech usa inc south san francisco usd hoffmannla roche inc nutley usd igen international inc pleasanton usd marcadia biotech inc nutley usd roche carolina inc florence usd roche diagnostics corporation indianapolis usd roche diagnostics hematology inc westborough usd roche diagnostics operations inc indianapolis usd roche health solutions inc fishers usd roche holdings inc south san francisco usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche tcrc inc new york usd spring bioscience corp pleasanton usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch hamilton uyu venezuela productos roche sa caracas vef vietnam roche vietnam co ltd ho chi minh city usd share capital less local currency units roche group notes roche group consolidated financial statements roche finance report significant accounting policies consolidation policy subsidiaries companies including structured entities group control group controls entity group exposed rights variable returns involvement entity ability affect returns power entity companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control associates companies group exercises power exercise significant influence control accounted using equity method segment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation annual financial statements presented swiss francs group companies use local currency functional currency certain group companies use currencies us dollars swiss francs euros functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs translated swiss francs using yearend rates exchange income statement statement cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average year end exchange rates taken directly comprehensive income roche finance report roche group notes roche group consolidated financial statementsrevenues sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid us similar rebates countries also deducted sales recorded accrued liabilities provisions deduction accounts receivable estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience circumstances level sales returns hence revenues reliably measured sales recognised right return expires generally upon prescription products patients revenues recorded earned services performed single transactions split separately identifiable components reflect substance transaction necessary conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research development activities expensed incurred following internal research costs incurred purpose gaining new scientific technical knowledge understanding internal development costs incurred application research findings knowledge plan develop new products commercial production development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation intangible assets met prior obtaining marketing approval regulatory authorities major markets postmarketing studies regulatory approval phase iv costs pharmaceuticals business generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured acquired inprocess research development resources obtained inlicensing arrangements business combinations separate asset purchases capitalised intangible assets acquired asset must controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy subsequent internal research development costs incurred postacquisition treated way internal research development costs research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition asset roche group notes roche group consolidated financial statements roche finance report licensing milestone upfront receipts royalty income recognised accrual basis accordance substance respective licensing agreements collectability royalty amount reasonably assured royalties recognised revenue cash received certain group companies receive upfront milestone similar payments third parties relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing obligation employee benefits shortterm employee benefits include wages salaries social security contributions paid annual leave sick leave profit sharing bonuses nonmonetary benefits current employees costs recognised within operating results employee rendered associated service group recognises liability profit sharing bonuses contractually obliged past practice created constructive obligation longterm employee benefits include longservice sabbatical leave longservice benefits longterm disability benefits expected costs benefits accrued period employment changes carrying value longterm employee benefit liabilities recognised within operating results termination benefits payable employment terminated group normal retirement date whenever employee accepts voluntary redundancy exchange benefits termination costs recognised earlier group longer withdraw offer benefits group recognises related restructuring costs pensions postemployment benefits defined contribution plans group contributions recognised within operating results employee rendered associated service prepaid contributions recognised asset extent cash refund reduction future payments available defined benefit plans liability recognised balance sheet present value defined benefit obligation less fair value plan assets changes net defined benefit liability recognised occur follows recognised income statement current service costs charged appropriate income statement heading within operating results past service costs including curtailment gains losses recognised immediately general administration within operating results settlement gains losses recognised general administration within operating results net interest net defined benefit liability recognised financing costs recognised comprehensive income actuarial gains losses arising experience adjustments difference previous assumptions actually occurred changes actuarial assumptions return plan assets excluding amounts included net interest net defined benefit liability change limit recognition plan assets excluding amounts included net interest net defined benefit liability net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit obligation interest effect limit recognition pension assets net interest calculated using discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments roche finance report roche group notes roche group consolidated financial statementspension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan equity compensation plans fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred leases group lessee finance leases exist substantially risks rewards ownership transferred group finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt finance lease assets depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method operating leases exist substantially risks rewards ownership transferred group payments made operating leases charged income straightline basis period lease group lessor certain assets mainly diagnostics instruments leased third parties finance operating lease arrangements finance lease assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method operating lease assets reported within property plant equipment lease income operating leases recognised lease term straightline basis roche group notes roche group consolidated financial statements roche finance report business combinations business combinations accounted using acquisition method accounting date acquisition group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest acquired business consideration transferred measured fair value date acquisition group acquire ownership acquired business noncontrolling interests recorded either fair value proportion fair value acquired net assets attributable noncontrolling interest directly attributable acquisitionrelated costs expensed incurred within general administration expenses goodwill goodwill arises business combination excess consideration transferred acquire business underlying fair value net identified assets acquired goodwill amortised tested impairment least annually upon occurrence indication impairment intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination initially recorded fair value available use intangible assets amortised straightline basis useful lives intangible assets reviewed impairment reporting date estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use years impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs sell value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm interest rate impairment loss arises useful life asset reviewed necessary future depreciationamortisation charge accelerated amount impairment loss subsequently decreases decrease related objectively event occurring impairment recognised previously recognised impairment loss reversed income statement impairment reversal impairment goodwill goodwill assessed impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units recoverable amount cashgenerating unit higher fair value less costs sell value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss impairment testing methodology described note inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses roche finance report roche group notes roche group consolidated financial statementsaccounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded objective evidence group able collect amounts due estimates based specific indicators ageing customer balances specific credit circumstances groups historical experience taking also account economic conditions expenses doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash equivalents readily convertible known amounts cash subject insignificant risk changes fair value maturity three months less date acquisition provisions contingencies provisions recognised legal constructive obligation incurred probably lead outflow resources reliably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise discounted time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available financial instruments financial instruments classified following categories disclosed note availableforsale nonderivative financial assets either designated classified financial asset category availableforsale assets initially recorded subsequently carried fair value changes fair value recorded comprehensive income except impairments interest foreign exchange components investment derecognised cumulative gains losses equity reclassified financial income expense availableforsale assets mainly comprised marketable securities fair value hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense fair value designated nonderivative financial instruments designated fair value profit loss initial recognition designated fair value instruments initially recorded subsequently carried fair value changes fair value recorded income statement designated fair value instruments mainly comprised contingent consideration liabilities changes fair value recorded general administration within operating results roche group notes roche group consolidated financial statements roche finance report loans receivables nonderivative financial assets fixed determinable payments quoted active market loans receivables initially recorded fair value subsequently carried amortised cost using effective interest rate method less impairment losses loans receivables mainly comprised accounts receivable cash cash equivalents financial liabilities nonderivative financial liabilities financial liabilities initially recorded fair value subsequently carried amortised cost using effective interest rate method financial liabilities mainly comprised debt trade payables financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred financial liability derecognised contractual obligations discharged cancelled expire impairment financial assets financial assets individually assessed possible impairment reporting date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale equity securities market value original cost market value original cost sustained sixmonth period considered impaired financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried comprehensive income difference original cost fair value impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held availableforsale reversal recognised directly comprehensive income hedge accounting group uses derivatives manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options group generally limits use hedge accounting certain significant transactions qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expense cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedging instrument recorded fair value effective portion hedge included comprehensive income ineffective portion reported financial income expense hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial item cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value nonfinancial item date recognition cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income expense forecasted transaction affects net income roche finance report roche group notes roche group consolidated financial statementsfair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future deferred tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values deferred tax assets recognised extent probable future taxable profit available unused tax losses utilised current deferred tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred taxes determined based currently enacted tax rates applicable tax jurisdiction group operates equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments held groups potential conversion obligations may arise groups equity compensation plans changes accounting policies group adopted following new standards amendments standards including consequential amendments standards date initial application january ias revised employee benefits ifrs consolidated financial statements ifrs joint arrangements ifrs disclosure interests entities ifrs fair value measurement presentation items comprehensive income amendments ias annual improvements ifrs cycle cycle cycle exception revisions ias material impact groups overall results financial position nature effects changes relevant groups financial statements explained roche group notes roche group consolidated financial statements roche finance report pensions postemployment benefits result ias revised group amended accounting policy respect basis determining income expense related defined benefit plans restated results retrospectively main changes follows revised standard eliminated option defer recognition actuarial gains losses defined benefit plans known corridor method group apply option rather uses option recognise gains losses directly comprehensive income option currently applied group requirement revised standard therefore change impact groups financial statements net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit obligation interest effect limit recognition pension assets net interest calculated using discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments previously expected income plan assets based estimated longterm rate underlying assets various plans impact restated results reduction net financial income million swiss francs year ended december ongoing impact beyond expected similar magnitude impact groups operating income net assets change past service costs recognised immediately income statement period plan amendment previously past service costs portion related unvested benefits deferred balance sheet progressively released impact change increase groups net assets million swiss francs december increase million swiss francs december following revision ias disclosed group also made presentational change income statement renamed financial income financial income expense moved caption financing costs reconciliations results published previously using previous accounting policy restated amounts reported comparatives using revised accounting policy presented restated roche group consolidated income statement millions chf year ended december application originally ias published revised restated operating profit associates financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group notes roche group consolidated financial statementsrestated roche group consolidated statement comprehensive income millions chf year ended december application originally ias published revised restated net income recognised income statement comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests restated roche group consolidated balance sheet selected items millions chf december december application application originally ias originally ias published revised restated published revised restated deferred tax assets defined benefit plan assets deferred tax liabilities defined benefit plan liabilities net assets net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity consolidation policy result ifrs group amended accounting policy determining whether control consequently whether consolidates investees group controls entity group exposed rights variable returns involvement entity ability affect returns power entity change impact groups financial statements fair values ifrs establishes single framework measuring fair value making disclosures fair value measurements measurements required permitted ifrss ifrs unifies definition fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date also replaces expands disclosure requirements fair value measurements ifrss including ifrs financial instruments disclosures accordance transitional provisions ifrs group applied new fair value measurement guidance prospectively provided comparative information new disclosures change impact measurements groups assets liabilities roche group notes roche group consolidated financial statements roche finance report presentation items comprehensive income result amendments ias group modified presentation items comprehensive income consolidated statement comprehensive income present separately items may reclassified income statement future would comparative information restated change change impact groups overall results financial position future new revised standards group currently assessing potential impacts new revised standards interpretations effective january beyond based analysis date group anticipate material impact groups overall results financial position roche finance report roche group notes roche group consolidated financial statementsreport roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework version issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set pages franz b humer alan hippe chairman board directors chief financial officer basel january roche group report roche management internal control financial reporting roche finance report report statutory auditor consolidated financial statements report statutory auditor consolidated financial statements annual general meeting roche holding ltd basel statutory auditor audited accompanying consolidated financial statements roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flows statement changes equity notes pages year ended december board directors responsibility board directors responsible preparation fair presentation consolidated financial statements accordance international financial reporting standards ifrs requirements swiss law responsibility includes designing implementing maintaining internal control system relevant preparation fair presentation consolidated financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion consolidated financial statements based audit conducted audit accordance swiss law swiss auditing standards international standards auditing standards require plan perform audit obtain reasonable assurance whether consolidated financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures consolidated financial statements procedures selected depend auditors judgement including assessment risks material misstatement consolidated financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation fair presentation consolidated financial statements order design audit procedures appropriate circumstances audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation consolidated financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion consolidated financial statements year ended december give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law roche finance report roche group report statutory auditor consolidated financial statementsreport legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag ian starkey franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche group report statutory auditor consolidated financial statements roche finance report report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examined roche groups system internal control financial reporting december based criteria established internal control integrated framework version issued committee sponsoring organizations treadway commission coso board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting responsibility express opinion companys internal control financial reporting based examination entitys internal control financial reporting process effected entitys board directors management personnel designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements conducted examination accordance international standard assurance engagements isae standard requires plan perform examination obtain reasonable assurance whether effective internal control financial reporting maintained material respects examination included obtaining understanding internal control financial reporting testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe examination provides reasonable basis opinion inherent limitations internal control financial reporting including possibility management override controls misstatements due error fraud may occur detected also projections evaluation internal control financial reporting future periods subject risk internal control may become inadequate changes conditions degree compliance policies procedures may deteriorate roche finance report roche group report independent auditor internal control financial reportingin opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework version issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg ag ian starkey franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche group report independent auditor internal control financial reporting roche finance report multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity noncontrolling interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards dividend proposed board directors applied retrospectively roche finance report roche group multiyear overview supplementary informationmultiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity noncontrolling interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards dividend proposed board directors applied retrospectively roche group multiyear overview supplementary information roche finance report sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche group multiyear overview supplementary informationadditions property plant equipment division millions chf pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total european union information based members eu december comparative information restated include new eu members whole fiveyear period roche group multiyear overview supplementary information roche finance report supplementary core results eps information groups basic diluted earnings per share given note annual financial statements allow transparent assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core results concept used internal management business based ifrs results following adjustments global restructuring plans see note excluded amortisation impairment intangible assets see note impairment goodwill see note excluded acquisition accounting onetime impacts alliance arrangements business combinations see financial review excluded discontinued operations currently none would excluded legal environmental expenses see financial review excluded global issues outside healthcare sector beyond groups control currently none would excluded material onetime treasury items major debt restructurings currently none would excluded pension plan settlements see note excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial review roche finance report roche group multiyear overview supplementary informationcore results reconciliation millions chf alliances normali global intangibles business legal pension sation restruc amorti intangibles combi environ plan ecp tax ifrs turing sation impairment nations mental settlements benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf alliances normali global intangibles business legal pension sation restruc amorti intangibles combi environ plan ecp tax ifrs turing sation impairment nations mental settlements benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests disclosed note roche group annual financial statements core results year ended december restated following accounting policy changes adopted adjustments made published ifrs results core results roche group multiyear overview supplementary information roche finance report divisional core results reconciliation millions chf alliances global intangibles business legal pension restruc amorti intangibles combi environ plan ifrs turing sation impairment nations mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf alliances global intangibles business legal pension restruc amorti intangibles combi environ plan ifrs turing sation impairment nations mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary informationcore eps basic core net income attributable roche shareholders chf millions weighted average number shares nonvoting equity securities issue millions core earnings per share basic chf core eps diluted core net income attributable roche shareholders chf millions increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions core earnings per share diluted chf disclosed note roche group annual financial statements earnings per share year ended december restated following accounting policy changes adopted resulted core earnings per share year ended december also restated roche group multiyear overview supplementary information roche finance report supplementary operating free cash flow information divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible assets impairment reversal property plant equipment impairment goodwill impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct utilisation provisions proceeds disposals total operating profit cash adjustments ebitda core operating profit depreciation impairment property plant equipment core basis ebitda margin sales group refined calculation free cash flow exclude impact employee stock options line peer group result operating profit cash adjustments year ended december restated exclude net cash flow equitysettled compensation plans resulted increase million swiss francs group operating profit cash adjustments year ended december divisional impacts increases million swiss francs pharmaceuticals million swiss francs diagnostics million swiss francs corporate roche finance report roche group multiyear overview supplementary informationsupplementary balance sheet information net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets disclosed note roche group annual financial statements taxation treasury net assets december restated following accounting policy changes adopted roche group multiyear overview supplementary information roche finance report r oche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased four roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january roche finance report roche group roche securitiesnumber shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number shares nonvoting equity securities genussscheine held total issue data per share nonvoting equity security chf earnings basic earnings diluted core earnings basic core earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend earnings basic diluted core earnings basic diluted equity attributable roche shareholders per share nonvoting equity security restated following accounting policy changes adopted disclosed note roche group annual financial statements information restated change accounting policy market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors roche group roche securities roche finance report ticker symbols share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche finance report roche group roche securitiesroche holding ltd basel financial statements notes financial statements summary significant accounting policies r isk management e quity board executive remuneration contingent liabilities board executive shareholdings ignificant shareholders appropriation available earnings report statutory auditor financial statements financial statements income statement millions chf year ended december income income participations interest income loans group companies interest investment income guarantee fee income group companies income total income expenses financial expenses administration expenses expenses total expenses profit taxes taxes net income roche finance report roche holding ltd basel financial statementsbalance sheet millions chf december december noncurrent assets participations longterm loans group companies total noncurrent assets current assets accounts receivable group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm legal reserve general legal reserve reserve equity instruments free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value roche holding ltd basel financial statements roche finance report notes financial statements summary significant accounting policies basis preparation financial statements roche holding ltd basel prepared accordance provisions swiss law participations major participations company listed note roche group annual financial statements valuation methods translation foreign currencies marketable securities equity instruments reported lower cost market value assets including participations reported cost less appropriate writedowns assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except participations translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred taxes tax charge includes corporate income capital taxes equity share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates equity instruments company purchased million roche shares purchase price swiss francs per share sold shares average sales price swiss francs per share december remaining roche shares net book value million swiss francs included marketable securities roche finance report roche holding ltd basel notes financial statementsmovement recognised amounts millions chf share legal free special available total capital reserve reserve reserve earnings equity january net income dividends december net income dividends transfer free reserve december net income dividends reserve equity instruments december contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december billion swiss francs billion swiss francs described note roche group annual financial statements pages significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalski hoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool december based information supplied group shares shares owned novartis ltd basel including affiliates thereof participation roche holding ltd basel notes financial statements roche finance report risk management detailed disclosures regarding risk management required swiss law included note roche group annual financial statements pages board executive remuneration board directors members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees remuneration members board directors thousands chf b gehrig hoffmann p baschera j bell p bulcke w burns l j r de vink c franz julius levinson oeri schwan b p r voser b weder di mauro total annual general meeting march prof gehrig mr de vink stand reelection b annual general meeting march dr schwan elected new member board directors remuneration included tables member corporate executive committee remuneration dr levinson includes payments consulting work board membership genentech totalling thousand swiss francs thousand swiss francs chairman board directors dr franz b humer received remuneration shown table remuneration chairman board directors thousands chf annual salary including cashsettled bonus bonus stock awards pensions postemployment benefits equity compensation plans employee benefits total remuneration received social security costs total annual shareholders meeting march proposed dr christoph franz elected chairman board directors succeed dr humer standing reelection roche finance report roche holding ltd basel notes financial statementscorporate executive committee members corporate executive committee cec roche holding ltd receive remuneration indirect benefits participate certain equity compensation plans shown table groups ceo dr severin schwan member cec highest total remuneration remuneration also disclosed new members cec mr diggelmann dr hippe included full calendar year joined cec similarly members cec retiring part way year dr soriot dr hunziker included full calendar year left cec remuneration members corporate executive committee thousands chf total cec schwan total cec schwan total cec schwan annual salary including cashsettled bonus bonus stock awards pensions postemployment benefits equity compensation plans retirement awards employee benefits total remuneration received social security costs total bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april total fair value employee thousand swiss francs fair value awards employee calculated taking account period blocked years years number awards fair value per award calculated grant date employer contribution social security schemes pension plans group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee equity compensation plans chairman board directors members corporate executive committee also participate certain equity compensation plans described terms vesting conditions awards disclosed note roche group annual financial statements fair values used roche group annual financial statements represent cost company grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions purposes remuneration disclosures values calculated based fair value employee receives taking account preliminary assessment completed performance conditions chairman board directors members corporate executive committee eligible participate roche connect programme enables employees make regular deductions salaries purchase nonvoting equity securities group contributes programme allows employees purchase nonvoting equity securities discount usually members corporate executive committee granted stocksettled stock appreciation rights ssars individual awards relating shown table fair value awards employees thousand swiss francs calculated using trinomial model american options roche holding ltd basel notes financial statements roche finance report members corporate executive committee granted restricted stock units rsus individual awards relating shown table fair value awards employees thousand swiss francs calculated based average market nonvoting equity security price day period prior grant date members corporate executive committee members senior management participate roche performance share plan psp group three overlapping threeyear psps target awards threeyear cycle defined beginning cycle awards considered form part employees remuneration three equal annual amounts threeyear cycle award result zero two nonvoting equity securities depending upon achievement performance targets discretion board directors individual awards relating shown table number awards calculated follows psp end cycle performance targets achieved accordingly participants received originally targeted nonvoting equity securities psp one nonvoting equity security per award psp one nonvoting equity security per award resulting allocations multiplied nonvoting equity security price december swiss francs give fair value remuneration received employee remuneration equity compensation plans schwan cec members total cec fair value fair value fair value number chf thousands number chf thousands number chf thousands roche connect employer contributions ssars awards rsus awards psp psp psp psp fair value total fair value employee benefits include tax advisory costs incidental benefits transactions former members corporate executive committee pensions totalling million swiss francs paid group former corporate executive committee members million swiss francs million swiss francs roche finance report roche holding ltd basel notes financial statements board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members board directors nonvoting equity securities shares genussscheine f b humer b b gehrig na na hoffmann c p baschera j bell p bulcke w burns b l j r de vink na na c franz julius levinson oeri c schwan na na b e p r voser b weder di mauro total include shares held shareholder group pooled voting rights b equity compensation awards roche option plan ssars rsus roche performance share plan see c mr hoffmann dr oeri held ubs longshort certificates roche shares ro versus roche nonvoting equity securities genussscheine rog mr de vink held roche american depositary receipts adrs e dr schwan appointed board directors march shareholdings disclosed tables member corporate executive committee roche holding ltd basel notes financial statements roche finance report corporate executive committee members corporate executive committee persons closely associated held shares nonvoting equity securities shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan ayyoubi r diggelmann hippe g keller b oday total equity compensation awards roche option plan ssars rsus roche performance share plan b close relatives dr keller held roche shares roche shares december chairman board directors mr burns members corporate executive committee held roche option plan awards rops stocksettled stock appreciation rights ssars shown table awards held dr humer current chairman board directors mr burns current member board directors issued previous capacities members corporate executive committee terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included business report part annual report pages rops ssars awards held december year issue total schwan ayyoubi r diggelmann hippe g keller oday total cec f b humer w burns total strike price chf b expiry date mar mar feb feb feb jan b feb dr hippes awards strike price chf expire april b mr diggelmanns awards strike price chf expire july roche finance report roche holding ltd basel notes financial statementsat december members corporate executive committee shown table held psp awards psp performance cycles terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report pages business report part annual report award result zero two nonvoting equity securities value adjustment depending upon achievement performance targets discretion board directors end cycle performance targets achieved accordingly participants receive originally targeted nonvoting equity securities total target number awards outstanding performance cycles december shown table roche performance share plan awards held december psp psp schwan ayyoubi r diggelmann hippe g keller oday total cec allocation date feb feb december chairman board directors mr burns members corporate executive committee time held total stocksettled stock appreciation rights outstanding total awards granted roche performance share plan roche holding ltd basel notes financial statements roche finance report appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account roche finance report roche holding ltd basel appropriation available earningsreport statutory auditor financial statements report statutory auditor financial statements annual general meeting roche holding ltd basel statutory auditor audited accompanying financial statements roche holding ltd comprise income statement balance sheet notes pages year ended december board directors responsibility board directors responsible preparation financial statements accordance requirements swiss law companys articles incorporation responsibility includes designing implementing maintaining internal control system relevant preparation financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion financial statements based audit conducted audit accordance swiss law swiss auditing standards standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures financial statements procedures selected depend auditors judgement including assessment risks material misstatement financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation financial statements order design audit procedures appropriate circumstances purpose expressing opinion effectiveness entitys internal control system audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion financial statements year ended december comply swiss law companys articles incorporation roche holding ltd basel report statutory auditor financial statements roche finance report report legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag ian starkey franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche finance report roche holding ltd basel report statutory auditor financial statementspublished cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking statements tel forwardlooking statements may identi fied words fax believes expects anticipates projects intends seeks estimates future similar expressions media office discussion among things strategy goals plans group communications intentions various factors may cause actual results differ basel switzerland materially future reflected forwardlooking tel statements contained annual report among others fax pricing product initiatives competitors legislative regulatory developments economic conditions delay investor relations inability obtaining regulatory approvals bringing products basel switzerland market fluctuations currency exchange rates general tel financial market conditions uncertainties discovery fax development marketing new products new uses existing products including without limitation negative results website clinical trials research projects unexpected side effects wwwrochecom pipeline marketed products increased government pricing pressures interruptions production loss order publications inability obtain adequate protection intellectual tel property rights litigation loss key executives fax employees adverse publicity news coverage email baselwebmasterrochecom statement regarding earnings per share growth profit next annual general meeting forecast interpreted mean roches march earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share roche trademarks mentioned enjoy legal protection roche finance report published german english case doubt differences interpretation english version shall prevail german text printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communicationse roche finance report f hoffmannla roche ltd finance report basel switzerland trademarks legally protected wwwrochecom